A paper-based point-of-care molecular diagnostic platform for the developing world by Rodriguez, Natalia Maria
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
A paper-based point-of-care
molecular diagnostic platform for
the developing world
https://hdl.handle.net/2144/14636
Boston University
BOSTON UNIVERSITY 
 
COLLEGE OF ENGINEERING 
 
 
 
 
 
Dissertation 
 
 
 
 
 
A PAPER-BASED POINT-OF-CARE MOLECULAR DIAGNOSTIC 
 
PLATFORM FOR THE DEVELOPING WORLD 
 
 
 
 
by 
 
 
 
 
NATALIA M. RODRIGUEZ 
 
B.S., Massachusetts Institute of Technology, 2009 
M.S.E., University of Pennsylvania, 2013 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2016  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 by 
 NATALIA M. RODRIGUEZ 
 All rights reserved  
Approved by 
 
 
 
 
 
First Reader ________________________________________________________ 
 Catherine M. Klapperich, Ph.D. 
 Associate Dean for Research and Technology Development 
 Professor of Biomedical Engineering 
 Professor of Mechanical Engineering 
 Boston University 
 
 
 
Second Reader ________________________________________________________ 
 Christopher S. Chen, M.D., Ph.D. 
 Professor of Biomedical Engineering 
 Boston University 
   
 Associate Faculty Member 
Wyss Institute for Biologically Inspired Engineering 
Harvard University 
 
 
 
Third Reader ________________________________________________________ 
 Mario Cabodi, Ph.D. 
 Research Assistant Professor of Biomedical Engineering 
 Boston University 
 
 
 
Fourth Reader ________________________________________________________ 
 Rajan Dewar, M.D., Ph.D. 
 Associate Professor of Pathology 
 University of Michigan 
  
 
 
Fifth Reader ________________________________________________________ 
 Allison Dennis, Ph.D. 
 Assistant Professor of Biomedical Engineering 
 Boston University 
	  	   iv 
 
 
For my mom, who has taught me by example to be fearless. 
  
	  	   v 
ACKNOWLEDGMENTS 
I’d like to extend my deepest gratitude to the following people who were a vital part of 
this journey: 
Cathie Klapperich: for welcoming me into your lab and guiding me into the 
Global Health field in which I have found my passion. Thank you for countless 
opportunities, for your generosity, warmth and humor, and for being such a positive 
influence in my life. 
Chris Chen: for teaching me how to ask the right questions, design the right 
experiments, and communicate my research in the most effective way possible, skills that 
made this dissertation possible and that I proudly take with me. Thank you for bringing 
me with you to Boston and supporting my transition to global health – I hope you know 
what that has meant to me. 
Mario Cabodi: for all your advice over coffee or Nutella, for always supporting 
me both scientifically and otherwise, and my warmest gratitude to you and Ann for 
offering me a wonderful crash pad so I could finish my thesis.  
Raj Dewar: I feel so very fortunate to have met you and to have had the privilege 
of learning so much from you in such a short period of time. Thank you for pushing me 
and enriching my PhD experience through diverse opportunities to collaborate with you.  
Allison Dennis: I appreciate your time and insights during this final stage of my 
PhD. 
To my labmates: Jackie Linnes, Andy Fan, Sharon Wong, Winnie Wong, Lena 
Liu, Constantinos Katevatis, George Pratt, Courtney Ellenson, Ravi Desai, Britta 
	  	   vi 
Trappmann, Jeroen Eyckmans, Brendon Baker, Sarah Stapleton, Anant Chopra, Grace 
Lin, Jordan Miller, Lin Gao, Christine Yoon, Esteban Toro, Michele Wozniak, Colin 
Choi. Thank you for your scientific and moral support throughout my PhD, and most 
importantly for your friendship. It was a privilege to work with and learn from all of you. 
To friends and family near and far (Marian, Nancy, Jessers, Puss, Rodrigo, Lelito, 
Sebas, Jonathan, Mara, Sarita, Lowie, Danielle, Diana y Felipe, my Masacote family, mis 
primitas Duran y Angies Orozco) and everyone who kept me sane through this journey – 
thank you for all the laughs, dances, wine chats, girls nights, phone calls and messages of 
support – I love you all. 
 To my beautiful family: Mami, Papi, Margui, Ban, Abella, Tia Ana, Tio Milan, 
Giovi, Sasa, Nenena, Pucho, Ninina, Puqui, Ia, Ela, and Ugo - you are the reason I have 
ever believed I can do anything and the reason I have never been afraid to fail. Thank you 
for your unconditional love and support, for everything you’ve taught me and all that 
you’ve done for me, and for being my cheering squad even when we are far apart. And to 
my new family: Aixa, Angel, Daniel and Abuelita Irma: thank you for your warmth and 
love, for your constant prayers, and for raising the man of my dreams. 
 And finally, to Manuel: for constantly inspiring me to ardently pursue what I love 
and to never settle, for making me want to be the best version of myself, and for loving 
me even when I’m not. Thank you for the light you bring to my life, for all our 
adventures, and those still to come. 
 
 
    
  
	  	   vii 
A PAPER-BASED POINT-OF-CARE MOLECULAR DIAGNOSTIC 
 PLATFORM FOR THE DEVELOPING WORLD 
NATALIA M. RODRIGUEZ 
Boston University College of Engineering, 2016 
Major Professor: Catherine M. Klapperich, Ph.D., Associate Dean for Research and 
Technology Development, Professor of Biomedical Engineering, 
Professor of Mechanical Engineering 
 
ABSTRACT 
 The disproportionate burden of infectious disease and lack of appropriate 
diagnostic tools in the developing world suggest that future health technology 
development efforts need to more effectively target these resource-limited settings. 
Microfluidic systems, like lab-on-a-chip technologies, offer the potential to miniaturize 
the large, complex processes performed in first-world laboratories onto a portable chip 
for use in remote settings. The problem with these systems is that they require equipment 
for fluidic handling and many other aspects of diagnostic assays such as sample 
preparation and analyte detection. The notion of “paperfluidics” has garnered much 
attention due to paper’s natural ability to wick fluids through capillary action without the 
need for pumps or other equipment. This and many other qualities of paper make it well 
suited for point-of-care diagnostics. 
Paper diagnostics have successfully been employed to detect the presence of 
antigens or small molecules in clinical samples; however, the detection of many disease 
targets relies on the much higher sensitivity and specificity of molecular diagnostics 
achieved via nucleic acid amplification tests (NAAT). The work presented in this 
	  	   viii 
dissertation describes the design and development of a paperfluidic sample-to-answer 
NAAT platform. Preliminary work focused on the development of separate NAAT 
modules for the extraction, amplification, and detection of nucleic acids from clinical 
samples directly within a paper matrix. A paper-based assay was developed, using 
Influenza A (H1N1) as a model system, for the extraction and purification of RNA 
directly from patient nasopharyngeal specimens, in situ isothermal amplification, and 
immediate lateral flow detection of amplified products.  
We then integrate these paper-based NAAT modules onto a single paperfluidic 
chip in a modular, foldable system that allows for fully-integrated fluidic handling from 
sample to answer. We showcase the full functionality of the chip by extracting, 
amplifying and detecting human papillomavirus (HPV) 16 DNA directly from crude 
cervical specimens in less than 1 hour, for early point-of-care detection of cervical 
cancer. The chip is made entirely of paper and adhesive sheets, making it low-cost, 
portable, and disposable, offering the potential for use in very remote settings and 
increasing access to screening to those most in need. 
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CHAPTER 1. INTRODUCTION 	  
1.1 Diagnostics for Global Health 
  
 In 2003, the Bill and Melinda Gates Foundation in partnership with the National 
Institutes of Health launched an initiative to fund research to advance the fight against 
diseases that disproportionately affect people in the world’s poorest countries. They 
identified 14 urgent needs in developing countries for new health-related technologies 
and announced them as the Grand Challenges in Global Health1. Two of the 14 Grand 
Challenges were related to diagnostics and measuring the health status of populations 
within these countries: Develop Technologies that Allow Assessment of Individuals for 
Multiple Conditions or Pathogens at Point of Care and Develop Technologies that Permit 
Quantitative Assessment of Population Health. Diagnostics are of utmost importance in 
addressing global health needs as they allow for prompt and appropriate treatment of 
disease, limiting the spread of disease, and minimizing waste of public resources. While 
many diverse advanced medical diagnostic technologies exist today, these were designed 
for the first world, for large hospital laboratories with air conditioning and electricity, 
well-maintained expensive equipment, refrigerated storage of assay reagents, highly 
trained technicians, and the appropriate infrastructure for rapid transportation of samples 
and proper handling of biohazardous waste. None of these things exist in many of the 
poorest places across the globe where the risk of infectious disease is highest1,2. Thanks to 
the Grand Challenges and other initiatives, there is a growing awareness for the need to 
develop diagnostic technologies that more effectively target low-resource settings.  
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  While traditional gold standard diagnostic methods have included sophisticated 
tools such as microscopy, enzyme-linked immunosorbent assays (ELISA), and 
polymerase chain reaction (PCR) based assays, the design constraints for the developing 
world severely limit their use and have forced biomedical engineers back to the drawing 
board. The World Health Organization has set guidelines for the development of 
diagnostics in resource-poor settings. These tests must be: affordable, sensitive, specific, 
user-friendly, rapid and robust, equipment-free, and deliverable to end users, 
corresponding to the acronym “ASSURED”3. 
 
1.2 Paper Microfluidic Diagnostics 
 
Microfluidic technologies, such as lab-on-a-chip and micro-total analysis systems 
(µTAS), allow for the miniaturization and integration of complex diagnostic assay 
functions onto a single chip.  Their use in remote settings has been perceived as 
potentially one of their most powerful applications by taking advantage of their small 
size, portability, low volume requirement for samples, and rapid analysis without the 
need for an expert operator1.  However, because these systems require pumps or pressure 
in order to drive fluid flow, they aren’t yet equipment-free and rely on instrumentation 
and electricity.  An alternative that has garnered much attention recently is 
“paperfluidics”, where paper is used as a substrate to construct microfluidic devices for 
use in rapid diagnostic tests4. Because of paper’s natural ability to passively transport 
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fluids through capillary flow, or wicking, this eliminates the need for pumps or 
equipment. 
Paper has many additional features that make it particularly appealing for 
resource-limited settings: it is inexpensive and abundant, made of cellulose which is 
compatible with biological samples, and white, which allows for visual and colorimetric 
readouts. Paper is thin and lightweight for easy storage and transportation, and it is 
flammable for easy incineration and disposal. Paper has been used for decades as an 
analytical chemistry platform, from pH indicator strips to lateral flow 
immunochromatographic strips commonly used as pregnancy dipstick tests, making it a 
promising and familiar substrate material 4 for rapid diagnostic tests. First pioneered by 
the Whitesides group, sheets of paper were patterned into regions of hydrophilic channels 
bounded by hydrophobic barriers through photolithography techniques5 and later through 
simple wax printing6. Since then, numerous techniques have been used to pattern paper 
for diagnostic devices, demonstrating it’s versatility and compatibility with many existing 
fabrication methods3.  
Thus far, the most successful applications of paper-based diagnostics have been 
chemical color-change reactions designed to detect small molecules, or antigen–antibody 
binding based immunoassays that can detect either an antigen or antibody present in a 
clinical sample4,7,8. The diagnosis of many infectious diseases, however, requires much 
higher sensitivity achievable via nucleic acid amplification tests, such as the polymerase 
chain reaction (PCR), that can detect small copy numbers of specific nucleic acid 
sequences.  
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1.3 Nucleic Acid Amplification Testing (NAAT) 
 
Nucleic acid amplification testing (NAAT) involves three main steps: (i) sample 
preparation, which involves sample lysis and nucleic acid extraction and purification, (ii) 
amplification of the extracted nucleic acids of interest to detectable copy numbers, and 
(iii) detection of the amplified products.  
 
1.3.1 Sample Preparation 	  
Sample preparation entails cell lysis and nucleic acid extraction steps, and has 
traditionally been a challenge in nucleic acid testing especially for POC applications 
because it involves lengthy, manual processes that often require expensive 
instrumentation, including centrifugation, extraction, and concentration of target nucleic 
acids to reach suitably low limits of detection9 The current gold standard in sample 
preparation for molecular diagnostics is the QIAGEN DNA/RNA extraction kit which 
can cost up to $5 per sample, can take up to 1 hour for processing, and requires 
centrifugation equipment and electricity. The Klapperich Lab has pioneered a fast and 
equipment-free single-step lysis, alcohol precipitation, and solid phase extraction process 
based on Chomczynski's method.10 Samples are mixed with a chaotropic lysis buffer 
containing guanidine thiocyanate to lyse cells and virions and denature and solubilize 
proteins, and alcohol and salt to precipitate the nucleic acids out of solution. The lysis 
buffer contains glycogen carrier particles that co-precipitate with the nucleic acids to 
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increase the effective hydrodynamic radius of precipitated nucleic acid aggregates. As 
nucleic acids (NA) are released into solution, they bind with the glycogen carrier particles 
to form glycogen-NA complexes. The solution is then flowed through a solid phase 
extraction column, glycogen-NA complexes get caught in the porous column, and waste 
flows through. Ethanol washes remove residual salts and contaminants. An air-drying 
step dehydrates the glycogen-NA complexes in place, stabilizing the sample for optional 
transport and storage, and elution of the samples from the column with nuclease-free 
water dissociates the complexes yielding a PCR compatible sample without the need for 
further purification11. Sample preparation at the point of care has been achieved using 
polymer micro-solid phase extraction columns12,13, and in the Klapperich laboratory we 
have even shown that DNA purification can be performed using these columns in low-
resource settings by pressurizing extractions with a bicycle pump11. 
 
1.3.2 Amplification and Detection of Target Nucleic Acids 	  
Amplification of nucleic acids at the point of care has typically been a challenge 
because of the need for expensive equipment and electricity to achieve the thermal 
cycling required by PCR to melt, anneal, and extend the DNA. To overcome this barrier, 
many successful isothermal amplification techniques have been developed that eliminate 
the need to melt DNA by taking advantage of enzymes that can either unwind the DNA 
strands or simply displace the strands during extension14. These enzymes enable the entire 
amplification process to occur at a single temperature, allowing for simpler heating 
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mechanisms like battery-powered resistance heaters15 or a portable heating system 
previously developed in our lab that consists of a Styrofoam cup and an iron oxide 
exothermic reaction provided by inexpensive, commercially available toe-warmers16.  
Many of these isothermal amplification methods also allow for the use of 
intercalating fluorescent dyes or the incorporation of a probe into the amplified product 
that can then be detected downstream. For detection of amplified products at the point of 
care, some groups have developed handheld UV light sources used in conjunction with a 
camera phone17 or relied on commercial lateral flow visual detection systems for probe 
detection. 
The isothermal amplification technique we will focus on in this dissertation is 
loop-mediated amplification (LAMP). By using a strand displacement polymerase, called 
Bst polymerase, amplification occurs without having to increase the temperature at each 
cycle to allow for DNA melting18,19. This method eliminates the need for thermal cycling 
equipment and dramatically reduces the cost of amplification as the reaction can be 
carried out at a constant temperature of 60- 65°C. The LAMP method uses four primers 
that recognize six regions on the target DNA. Strand displacement occurs from the four 
primer regions and DNA loops are formed at the 5’ and 3’ ends, creating a double loop, 
or dumbbell structure. Loop primers can then be designed to specifically recognize these 
loop regions such that amplification can initiate from six different regions, making the 
method much faster than PCR (results can be obtained within 20 minutes to 1 hour). 
Additionally, these loop primers can be tagged with probes that allow for the fast and 
	  	  
7 
easy detection of amplified products on commercially available lateral flow strips (used 
in pregnancy tests)20.  
In our assays, forward and reverse loop primers were tagged with fluorescein 
isothiocyanate (FITC) and biotin, respectively, to enable immediate downstream 
detection of the amplified products on anti-FITC lateral flow strips (Figure 1a). The strips 
consist of a sample pad where the sample is loaded, a conjugate pad that contains 
streptavidin-conjugated beads, a detection strip where the control and test lines are 
spotted, and an absorbent pad to direct wicking (Figure 1b). During amplification, loop 
primers tagged with FITC and biotin are incorporated into the amplicons, the biotin probe 
binds to the streptavidin conjugated beads, which can then aggregate at the test line (anti-
FITC), forming a visible line to indicate a positive LAMP reaction. The control line 
(biotin) binds excess streptavidin beads, creating a visible positive control to show 
whether the flow strip worked properly. As shown in Figure 1c, a positive result is 
indicated by two lines, and a negative result is indicated by one line.  
The simplicity, rapidity, and excellent sensitivity and specificity make this 
method well suited for use in primary care or low-resource settings. 
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Figure 1. LAMP-based detection method. A) Loop primers are tagged with FITC and biotin 
probes. B) Lateral flow detection strip schematic. The test line consists of anti-FITC antibodies, 
and the control line is biotin. C) Positive and negative LAMP results on lateral flow detection 
strips. 	  
1.3.3 NAAT Steps in Paper Matrices 	  
Translating NAAT to a paper matrix format is the first step in developing a 
paperfluidic molecular diagnostic platform and a number of advances have been made in 
each of these individual steps.  
Dried-blood spot (DBS) testing, the first form of paper-based DNA capture 
employed in remote settings, has been used for decades to store DNA from heel or finger 
prick blood samples on filter paper for downstream testing in remote settings21,22. More 
recently, DNA extraction and purification via filtration through a paper matrix has also 
been reported23,24. Recent work in the Klapperich lab demonstrated successful DNA 
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extraction from paper extraction matrices made of compressed chromatography paper25. 
Other groups have developed paper “microfluidic origami” systems for cell lysis and 
DNA extraction24. While these studies have demonstrated the efficacy of paper-based 
sample preparation systems that allow for elution of purified nucleic acids for 
downstream PCR analysis, a major challenge remains: how to integrate these extraction 
modules with the downstream amplification and detection steps required for a ‘sample-
to-answer’ total analysis system. The typical bind-wash-elute strategy used in DBS and 
paper-based extraction systems requires off-chip elution and also means that the extracted 
nucleic acid will be diluted prior to analysis, which may be undesirable in situations 
where low concentrations result in suboptimal detection sensitivities. 
Our group and others have shown that molecular amplification of nucleic acids is 
achievable in a paper-based format25-29. Some of the most important work in this space to 
date is summarized in Table 1. The Klapperich Lab has previously reported the capture of 
Chlamydia trachomatis bacterial cells onto paper supports followed by in situ isothermal 
helicase dependent amplification (tHDA) and lateral flow detection of DNA in a 
pressure-driven system25. Ali et al. and Rohrman et al. separately demonstrated 
isothermal amplification of DNA in a paper matrix followed by fluorescent imaging or 
lateral flow detection, respectively26,27. Both studies, however, required traditional bench 
top nucleic acid sample preparation prior to amplification.  Gan et al. developed a paper-
based DNA extraction chip with the capability to perform PCR directly on-chip; 
however, this method involved substantial off-chip instrumentation including a syringe 
pump to drive fluid flow, a thermal cycler for PCR, and a separate downstream gel 
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electrophoresis step for detection of PCR products28. Liu et al. demonstrated combined 
paper-based capture and amplification of RNA in which target RNA was spiked into the 
sample, not directly extracted from clinical specimens, and the detection method required 
a fluorescence reader interfaced with a computer, limiting utility in the field29. Connelly 
et al. has recently reported the only other device to date that fully integrates paper-based 
extraction, amplification and detection steps, using a magnetic sliding strip to run each 
step serially17. However, this device was not equipment-free, as it relied on a UV light 
source and camera phone, and was not demonstrated with crude clinical samples.	  
 
 
Table 1. Previous work in paper-based NAAT 
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CHAPTER 2. PAPER-BASED NAAT MODULES FOR INFLUENZA A (H1N1)  	  
2.1 Introduction 	  
  
The 2009 Influenza A (H1N1) pandemic caused an estimated global mortality of 
284,400 deaths worldwide, more than half of which occurred in developing countries in 
Southeast Asia and Africa30. This disproportionate number of deaths suggests that efforts 
to prevent future pandemics need to more effectively target these developing regions. The 
standard molecular diagnostic approach for H1N1 virus infection is currently laboratory 
sample preparation followed by nucleic acid amplification and detection by real-time RT-
PCR31. However, expensive equipment, highly skilled technicians, and established 
laboratory and transportation infrastructure requirements make this method unsuitable for 
use in resource-limited settings. Immunoassay-based rapid diagnostic tests (RDTs) offer 
a faster, lower-cost solution for resource-limited settings, but they suffer from low test 
sensitivities and specificities, commonly resulting in false negative and/or false positive 
detection32. Thus, strategies that combine the high sensitivity and specificity of nucleic 
acid amplification with the rapid, portable, and low-cost nature of RDTs are needed to 
facilitate clinical care, infection control, and epidemiological investigations in these 
settings2. 
Influenza A (H1N1) is an RNA virus, and RNA targets are known to present 
additional challenges for point-of-care diagnostics. In contrast to DNA, RNA is much 
less stable, has a high risk of degradation by ubiquitous RNAses in biological samples 
and the environment, and typically involves a reverse-transcription step by an additional 
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enzyme in most amplification methods, adding to the complexity of the assay. 
Nonetheless, the need for RNA point-of-care diagnostics is becoming increasingly 
apparent following the 2009 Influenza pandemic, and the very recent Ebola epidemic in 
resource-limited settings in Africa33. 
To address these challenges, and as a first step towards an integrated paperfluidic 
molecular diagnostic chip, we first aimed to design individual paper-based modules for 
nucleic acid extraction, amplification, and detection. We sought to develop a paper-based 
RNA extraction method that allows for an in situ RNA amplification reaction to occur 
directly in the same paper extraction matrix without the need for off-chip elution. We 
used a rapid, isothermal, reverse-transcription loop-mediated amplification assay (RT-
LAMP), which eliminates the need for a thermal cycler19. Additionally, we designed the 
RT-LAMP assay to incorporate probes for immediate downstream visual detection on an 
immunochromatographic, or a lateral flow detection (LFD) test strip, like those used in 
common pregnancy tests, further eliminating the need for detection equipment.  
Influenza A (H1N1) RNA was chosen as a model disease to use as starting 
material for the development of paper-based nucleic acid testing modules for several 
reasons. The Klapperich lab has much experience working with Influenza A virus 
RNA34,35, an approved Institutional Review Board protocol, and clinical samples from the 
2009 swine-flu season which include many H1N1-positive patient nasopharyngeal swab 
and aspirate samples. As described in this chapter, we developed a paper-based assay that 
incorporates all three RNA extraction, amplification, and detection steps directly from 
human clinical specimens without the need for centrifuges or other sample preparation 
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equipment, thermal cyclers, pumps, pressure, or detection instrumentation of any kind. 
This work culminated in a publication in Analytical Chemistry where we reported a rapid, 
equipment-free, paper-based assay for the extraction and purification of Influenza A 
(H1N1) RNA from patient nasopharyngeal specimens, followed by in situ isothermal 
amplification directly within the same paper extraction matrix, and immediate visual 
detection via paper lateral flow test strips, for point-of-care, sample-to-answer 
functionality in 45 minutes36.  This published work has been adapted in this chapter with 
permission from Rodriguez NM, Linnes JC, Fan A, Ellenson CK, Pollock NR, Klapperich 
CM. Paper-Based RNA Extraction, in Situ Isothermal Amplification, and Lateral Flow 
Detection for Low-Cost, Rapid Diagnosis of Influenza A (H1N1) from Clinical 
Specimens. Analytical Chemistry 2015;87(15):7872–9. Copyright 2015 American 
Chemical Society. 
 
2.2 Materials and Methods 
 
H1N1 in vitro Transcribed RNA Standards 
In vitro RNA standards containing the target loci for both RT-LAMP and the 
qRT-PCR assays were synthesized by cloning the hemagglutinin (HA) gene from a 
deidentified patient sample that tested positive for influenza A 2009 (H1N1). Genomic 
RNA from the patient sample was extracted via the QIAamp Viral RNA Mini Kit 
(Qiagen) and reverse-transcribed with the Superscript III First-Strand Synthesis Kit 
(Invitrogen) with a gene-specific reverse primer. The target region on the HA gene, from 
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nucleotide 351 to 1735, was PCR amplified with the Phusion High-Fidelity PCR kit 
(New England BioLabs), purified via a QIAquick Gel Extraction kit (Qiagen), and cloned 
into the pGEM-T Easy vector (Promega). Plasmids were isolated with a Plasmid Midi 
Prep Kit (Qiagen), blunt-cut linearized, and served as in vitro transcription DNA 
templates using a Ribomax Transcription kit (Promega). The RNA transcripts were then 
purified via DNAse digestion, acid phenol-chloroform extraction and ethanol 
precipitation. The concentration of the purified RNA was determined by measuring the 
OD260 with the NanoDrop ND-2000c apparatus (Thermo Scientific). The target RNA 
copy number was calculated, and 50 µl aliquots were made and stored at -80 ºC. 
 
RT-LAMP Assay in Solution 
A reverse-transcription loop-mediated amplification (RT-LAMP) assay was 
developed and optimized for rapid, isothermal amplification and detection of the 
hemagglutinin (HA) gene of the Influenza A (H1N1) 2009 pandemic virus strain. The 
reaction was carried out in a final volume of 25 µL with 5 µL of the RNA sample, 2 U 
large fragment Bst 2.0 DNA polymerase and 1x Isothermal Amplification Buffer (New 
England Biolabs), 2 U Thermoscript Reverse Transcriptase (Life Technologies), 0.2 M 
Betaine, 8 mM MgSO4, 1 mM each dNTP, 3.75 pmol each of forward and reverse outer 
primers (F3 and B3), 7.5 pmol each of forward and reverse loop primers (LF and LB), 30 
pmol each of forward and reverse inner primers (FIP and BIP), and 0.25 µL of 20X 
EvaGreen and 0.75 µL  of 0.002X ROX reference dyes for real-time quantitative 
analysis. Because we found our RT-LAMP assay was sensitive to reagent freeze-thaw 
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cycles, multiple aliquots of each assay component were made and frozen down initially, 
and a fresh aliquot was used each time. The reaction was run for 20 minutes at 65 ºC. 
Primer sequences previously designed by Kubo et al. were used for the specific 
amplification of segment 4 of the HA gene of the 2009 pandemic strain37 and are listed in 
Table 2. Forward and reverse loop primers (LF and LB) were tagged with Fluorescein 
isothiocyanate (FITC) and biotin, respectively, to enable downstream detection of the 
amplified products on immunochromatographic, lateral flow detection (LFD) test strips 
(Ustar Biotechnologies). 
Following amplification, the RT-LAMP assay products were analyzed by 2% 
agarose gel electrophoresis, LFD strips, or both. The LFD strips consist of a sample pad 
where the sample is loaded, a conjugate pad that contains streptavidin-conjugated gold 
nanoparticles, a detection strip where the control and test lines are spotted, and an 
absorbent pad to direct wicking. During amplification, loop primers tagged with FITC 
and biotin are incorporated into the amplicons. The biotin probe on the amplicon binds to 
the streptavidin conjugated gold nanoparticles, which then aggregate at the test line (anti-
FITC) as the FITC probe gets captured, forming a visible red line to indicate a positive 
LAMP reaction. The control line (biotin) binds excess streptavidin coated gold-
nanoparticles, creating a visible positive control to show whether the flow strip worked 
properly. 
Additionally, the specificity of the product was confirmed by restriction enzyme 
digestion with the HindIII restriction endonuclease (New England Biolabs) with a cutting 
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site between FIP and BIP19. Following digestion at 37°C overnight, the digested 
products were analyzed by 2% agarose gel electrophoresis. 
LFD strips were imaged using an iPhone 5 camera (Apple). No post-processing 
was required for analysis. LFD test line and control line intensities were analyzed using 
the Gel Analysis feature in ImageJ (National Institutes of Health). For each LFD strip, the 
intensity of the test line was divided by the intensity of the control line to obtain the 
percentage of control intensity for each sample. Although control line intensities may 
vary across strips, normalizing our test line intensity values to the control line ensured a 
proper reference for each test strip and allowed us to control for any potential variability 
during manufacturing (amount of gold nanoparticles impregnated in each conjugate pad) 
or imaging (lighting or distance from strip, which were not controlled for). Unpaired, 
two-tailed Student’s T-tests were used to determine the significance of each sample 
compared to the experimental negative control sample. 
 
qRT-PCR 
The RNA extraction yields were ascertained via quantitative, reverse-transcription 
PCR (qRT-PCR).  Using the Brilliant II RT-PCR kit (Agilent), PCR was performed on an 
Applied Biosystems 7500 thermocyler under the following conditions: 60 min at 50°C 
for RT, 10 min at 95°C for polymerase activation, followed by 40 cycles of 30 sec at 
95°C, 30 sec at 55°C for primer annealing, and 1 min at 60°C for amplification. Five 
microliters of the extracted RNA was used as the template in a 25 μL reaction mixture.   
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The influenza A (H1N1) and SW H1-specific TaqMan loci used in this PCR were 
identical to the ones recommended by the CDC38 and are listed in Table 2.   
In each qRT-PCR run, a cycle threshold (CT) versus RNA concentration standard 
curve was generated from a 5-log dilution series of our in vitro transcribed H1N1 RNA 
standards.  For each patient sample, the effective viral RNA concentration was 
quantitated via standard curve interpolations. 
 
RT-PCR Fwd 
Rev 
Probe 
5’ - gtgctataaacaccagcctYcca 
5’ - cgggatattccttaatcctgtRgc 
5'NED - cagaatatacatccRgtcacaattgga -MGB 
RT-LAMP F3 
B3 
FIP 
BIP 
LF 
LB 
5’ - gctaagagagcaattgagc 
5’ - atgtaggatttgctgagct 
5’ - cgagtcatgattgggccatgacagtgtcatcatttgaaaggttt 
5’ - aaggtgtaacggcagcatgtccgaatttccttttttaactagccat 
5’FAM-acttgtcttggggaatatctc 
5’Biotin-atgctggagcaaaaagct 
Note: Symbol R indicates mixed bases A,G and symbol Y indicates mixed bases C,T. 
Table 2. Influenza A (H1N1) Primer Sequences 
 
Screening of Paper Materials for in situ Amplification 
Five different types of paper materials representing a range of thicknesses, matrix 
compositions, porosity, fluidic absorbance, and protein/DNA-binding properties were 
screened for their ability to support LAMP in a matrix-based format and to effectively 
capture precipitated glycogen-RNA complexes: Cellulose chromatography paper (CHR), 
0.22 μm polyethersulfone (PES), 0.2 μm polycarbonate (PC), 1.6 μm glass microfiber 
(GF), and 0.45 mm nitrocellulose (NC). CHR, GF, and NC were purchased from GE 
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Healthcare (Pittsburgh, PA, catalog numbers 3MM CHR, GF/G, and Protran BA85, 
respectively). PES and PC were purchased from Millipore EMD (Billerica, MA), catalog 
numbers GPWP04700 and GTTP14250, respectively. 
The fluidic absorbency of each of the five different paper materials was measured 
by calculating the difference in weight before and after submerging a 1 cm by 1 cm 
square of the material in water. The materials were submerged until fully wetted and then 
gently blotted onto a polystyrene weight dish to remove excess liquid before weighing. 
Measurements were taken using five replicate samples for each paper. The average and 
standard deviation of the water absorbency were calculated from the replicate samples.  
All amplification experiments were carried out in individual 0.2 ml reaction tubes 
containing CHR, PES, PC, GF, or NC. An additional positive control reaction containing 
DNA without paper and a negative reaction control containing master mix and nuclease-
free water only were included in every experiment. For experiments testing amplification 
in the presence of a paper matrix, 6 mm diameter hole punches of each paper material 
were used. None of the 6 mm hole punches held a full 25 µL of reaction liquid. 
Therefore, for experiments testing amplification completely within a paper matrix, 
materials were cut to the appropriate size needed to absorb the 25 µL reaction based on 
their measured fluidic absorbency. The sizes used for amplification within paper without 
excess liquid were 0.6 cm2, 0.6 cm2, 1.8 cm2, 0.3 cm2, 0.9 cm2 for CHR, PES, PC, GF, 
and NC, respectively. 
Cut or hole-punched paper materials were placed into PCR strip-tubes. Five 
microliters of the RNA or DNA templates were pipetted directly onto each of the paper 
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membranes. Twenty microliters of the appropriate amplification master mix were then 
added directly onto each of the paper surfaces. The tubes were incubated at 65°C for the 
20-min LAMP reaction. Following amplification, a hole was made at the bottom of each 
tube using a sterile 18-gauge syringe needle. The tubes were stacked onto a clean 96-well 
plate and centrifuged at 2500 rpm for 1 minute to elute any liquid absorbed by the papers 
and collect it into the plate wells. All experiments were repeated three separate times for 
every reaction condition. This work was performed in collaboration with a postdoctoral 
researcher in the Klapperich lab, Dr. Jacqueline Linnes and has been submitted for 
publication.39 
 
Paper Extraction Setup 
A 0.8 x 0.8 cm (0.64cm2) piece of polyethersulfone (PES) filter paper with a 0.2 
μm pore size (Millipore, cat# GPWP04700) was placed on top of a cellulose (Whatman 
GB003 blotting paper, cat# 10426972) absorbent pad cut to absorb approximately 400 µl 
of liquid waste. The absorbent pad was shaped as a 6 cm long sector that extended 
radially from 0.5 cm at the base of the top sheet inlet port to an ultimate width of 2 cm. 
This sector angle was optimized to achieve the appropriate flow rate as the volume of 
liquid absorbed by the pad per unit time has been previously determined to be linearly 
related to the angle of the sector shape40.  The PES and absorbent pad were placed into a 
custom-designed 0.635 x 3.5 x 7.5 cm acrylic fixture and aligned with the inlet port in the 
top acrylic sheet (Figure 2). The fixture was designed in SolidWorks and was cut out of 
acrylic sheets using a 30W Epilog Zing laser cutter (speed=5, power=100, 
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frequency=5000). The bottom sheet was rastered (speed=100, power=60) with the same 
dimensions as the absorbent pad to ensure its secure placement. The extraction setup was 
held together using 32mm binder clips  (Figure 2). 
 
 
Figure 2. Paper extraction setup 
 
Paper Extraction Procedure  
Based on a single-step lysis, RNA extraction, and alcohol precipitation recipe 
developed by Cao et al., 25 µL of the NPS specimen was mixed with 75 µL lysis buffer 
(2 M GuSCN, 66.7% 2- propanol, 1x RNASecure (Ambion))35 and 3 µL of 15 mg/mL 
Glycoblue coprecipitant (Life Technologies). This mixture was pipetted onto the PES 
membrane through the extraction setup inlet port. The prevailing capillary forces 
generated by the absorbent pad quickly wick the liquid phase away from the membrane 
surface, thus leaving the solid phase behind. As a result, the RNA-Glycoblue precipitate 
remains on the PES membrane producing a visible blue film (Figure 8a). The PES 
membrane was then rinsed sequentially with 200 µL of 70% ethanol and 100 µL of 100% 
ethanol, which were also wicked away from the inlet port by the absorbent pad. The PES 
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membrane was physically removed from the extraction setup with forceps and placed into 
a 0.2 mL tube. Tubes were left open for 2 minutes to allow the PES membrane to dry. 
For extraction quantification experiments, the PES membrane was placed into a 
0.2 mL tube with 100 µL of nuclease-free water and vortexed to dissolve the RNA-
Glycoblue complexes and release the RNA into solution. The tube was inverted and a 
small hole was pierced through the bottom of the tube using a sterile needle (BD Ultra-
Fine™ 30 Gauge Lancets, cat# 325773). The tube was then stacked inside a larger 1.5 
mL Eppendorf tube, and centrifuged at 2500 RPM for 1 minute to elute the extracted 
RNA completely out of the PES and into the Eppendorf tube for downstream qRT-PCR 
analysis.  
Paper extractions were compared to traditional centrifugation extraction methods, 
where instead of capturing the RNA in paper, we precipitate it by centrifugation, and 
wash and resuspend the pellet. Briefly, 25 µL RNA solutions mixed with 75 µL lysis 
buffer were centrifuged at 13,000 RPM for 15 minutes at room temperature until a blue 
pellet was visible at the bottom of the tube. The supernatant was removed, and 100 µl of 
70% ethanol was added to the tube and centrifuged at 13,000 RPM for 5 minutes at room 
temperature. The supernatant was removed and 100 µL of 100% ethanol was added to the 
tube and centrifuged a final time at 13,000 RPM for 5 minutes. All centrifugation steps 
were performed in an Eppendorf centrifuge model 5424R. The supernatant was removed 
and tubes were left open for pellets to dry at room temperature on the bench top for 10 
minutes. The pellets were resuspended in 100 µL nuclease-free water and RNA was 
quantified using qRT-PCR. 
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Paper extraction and in situ RT-LAMP Assay 
 
For in situ RT-LAMP experiments, the sample was extracted in the paper 
extraction set-up as described above, and the extracted RNA precipitated onto the PES 
was amplified directly within the PES matrix. Our group previously investigated the 
effect of different paper materials on isothermal amplification within the paper matrices 
and has reported on the success of LAMP within PES membranes39. The 25 µL RT-
LAMP reaction mix was pipetted directly onto the RNA-Glycoblue-containing 0.64 cm2 
PES membrane and was fully absorbed by the PES. This size of PES required to 
completely absorb 25 µL of liquid had been calculated using the previously determined 
water absorbency of PES of 38.82 µL /cm2.39 The soaked PES was left in the 0.2 mL tube 
with the lid closed to prevent evaporation and incubated in a 65°C heat block for 23 
minutes. Following amplification, the soaked PES containing the entire RT-LAMP 
reaction volume was placed directly onto the sample pad of the LFD strip using forceps, 
and the LFD strip and PES were placed between two acrylic sheets aligned with the inlet 
port (Figure 3) and the setup was held together with 32 mm binder clips. 50 µL of 
nuclease free water was then pipetted into the inlet port, filtered through the PES, and 
wicked onto the LFD strip for immediate detection of amplified products.  
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Figure 3: Lateral Flow Detection elution setup 
 
Clinical Nasopharyngeal Specimens 
Nasopharyngeal swab (NPS) samples were collected during the 2009 influenza A 
(H1N1) pandemic period from patients at Beth Israel Deaconess Medical Center 
(BIDMC) during a previously described study that had been reviewed and approved by 
BIDMC’s institutional review board35. Briefly, discarded NPS specimens that had been 
taken during routine clinical care for testing ordered by the patient’s clinician were 
collected and frozen. The NPS specimens were taken using two Copan flocked swabs 
(COPAN). The first swab was inserted flat and pushed forward with gentle downward 
pressure on the lower nasal floor to the posterior wall of the nasopharynx, where it was 
rotated for a few seconds to collect cellular material. The swab was withdrawn and 
placed into sterile 1X PBS. The collection procedure was repeated using the second 
flocked swab in the other nostril; the second swab was placed into M4RT (Remel) media 
for viral culture. The two swabs were then submitted on ice to the BIDMC microbiology 
laboratory. After routine testing, specimens (approximately 1.0 mL) were stored at -80°C. 
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The frozen NPS specimens were later deidentified and sent to the Klapperich Laboratory 
where they were aliquotted and stored at -80°C.  
For gold standard extraction experiments, RNA was extracted from 140 µL of 
each specimen using the QIAamp Viral RNA Mini Kit (Qiagen). 
 
2.3 Results and Discussion 	  
H1N1 RT-LAMP Assay in Solution 
Before developing the in situ amplification assay, we first optimized a protocol 
for RT-LAMP amplification of H1N1 RNA in solution. The H1N1 RT-LAMP assay was 
optimized using our in vitro transcribed H1N1 RNA standards. We set a target lower 
limit of detection of 10^5 cp/mL, since the mean pre-treatment H1N1 viral load in nasal 
specimens has been reported to be ~10^8 cp/mL with typical viral loads between 10^6 
and 10^10 cp/mL, and patients below 10^5 cp/mL generally had not yet begun to exhibit 
symptoms35,41,42. The RT-LAMP reaction incubation time at 65 ºC required to reach our 
target lower limit of detection of 10^5 cp/mL was determined by amplifying 10-fold 
serial dilutions of in vitro transcribed target RNA (from 10^10 to 10^5 cp/mL) using 
EvaGreen and ROX reference dyes for real-time quantification of amplification. With our 
final optimized assay conditions, we were able to amplify 10^5 cp/mL (a net 500 copies 
per sample) to detectable levels within 20 minutes (Figure 4a). To ensure specificity of 
the primers for the HA gene of the H1N1 strain, in vitro transcribed RNA from a 
different gene of the influenza A viral genome, the matrix protein-encoding M1 gene, 
was also tested at a high concentration of 10^10 cp/mL. There was no amplification of 
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the negative (NTC) control or of the M1 gene, demonstrating H1N1 strain specificity. 
Amplification results were confirmed by 2% agarose gel electrophoresis (Figure 4b) and 
lateral flow detection (Figure 4d).  
 LFD strips produced visible test lines for positive reactions, enabling immediate 
detection of amplified products with the naked eye. Test line intensities were quantified 
as a percentage of control line intensities and results from three independent experiments 
are plotted in Figure 4d. Although lower in intensity, our LFD strips still exhibit a clear, 
visible test line down to 10^5 cp/mL that is statistically different from the negative 
control.  
 Additionally, to confirm that RT-LAMP products specifically correspond to the 
correct H1N1 target sequence, the amplified products were digested with the HindIII 
restriction endonuclease and analyzed by agarose gel electrophoresis (Figure 4c). The 
Influenza A (H1N1) HA gene sequence contains a single HindIII cutting site between the 
FIP and BIP regions, and digested products were in agreement with the expected sizes 
previously determined by Kubo et al.37, confirming the specificity of our product.  
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Figure 4. Influenza A (H1N1) RT-LAMP Assay in solution. a) Real-time RT-LAMP 
amplification of in-vitro transcribed H1N1 RNA standards from 10^10 cp/mL down to 10^5 
cp/mL. NTC = no template control. b) 2% Agarose gel electrophoresis of RT-LAMP products. 
L= 100bp DNA ladder, 10 = 10^10 cp/mL, 9 = 10^9 cp/mL, etc. NTC = no template control. M1 
=  M1 gene in vitro transcribed standards, 10^10 cp/mL. c) HindIII digestion of RT-LAMP 
products. d) Representative lateral flow strips from three independent experiments show detection 
of RT-LAMP products. Top line is the flow strip control line, bottom line is test line.  Test line 
intensity as percentage of control line intensity for three experiments is plotted. (* p < 0.05, ** p 
< 0.01, *** p < 0.001, ns = not significant). Figure from: Rodriguez et al., Analytical Chemistry, 
2015 
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Screening paper materials for in situ amplification 
The fluidic absorbency measurements for each paper material are shown in Figure 
5 and were 88 µL/cm2 (± 4.2), 46 µL/cm2 (± 2.3), 37 µL/cm2 (± 6.4), 14 µL/cm2 (± 0.4), 
and 20 µL/cm2 (± 5.8) for GF, CHR, PES, PC and NC, respectively. Using these fluidic 
absorbency values, the size of each paper material needed to absorb the full volume of an 
amplification reaction mix (25 µL ) was calculated. The CHR, PES, PC, GF, and NC 
were cut into the corresponding size: 0.6, 0.6, 1.8, 0.3, and 0.9 cm2, respectively, in order 
to perform nucleic acid amplification within the paper matrices without excess reaction 
liquid. 
 
Figure 5. Fluidic absorbency of paper materials (n=5) 
 
 
Isothermal amplification of Influenza A (H1N1) RNA via RT-LAMP occurred in 
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the positive control, amplification in these membranes was statistically significantly 
greater than the negative controls (p < 0.02 for each). Amplification was inhibited by the 
presence of GF and NC, as determined by agarose gel electrophoresis and LFD strips, 
shown in Figure 6. In some cases, amplification of RNA was able to occur in the 
presence of the GF and NC, but results were inconsistent and inhibited compared to other 
matrices. RT-LAMP resulted in successful amplification of Influenza A (H1N1) RNA 
when performed completely within the PES and PC matrices. PES, PC, and the positive 
control all resulted in statistically significant amplification compared to the negative 
control (p < 0.001). However, the amplification was inhibited when performed 
completely within CHR, GF and NC matrices, as determined by agarose gel 
electrophoresis and LFD strips, shown in Figure 6. While not statistically significant, a 
small amount of amplification did occur in experimental replicates in the presence of 
CHR. Additionally, detectable RNA amplification occurred within the GF matrix as well, 
however, these were faint and not statistically significant versus the negative control. 
Thus, we selected PES and PC for further screening for their ability to effectively capture 
the RNA-glycogen complexes. 
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Figure 6. Results of Influenza A (H1N1) RT-LAMP performed in the presence of each 
paper membrane (Left) and completely within each paper membrane (Right). Detection by 
agarose gel electrophoresis (a) and LFD strips (b). Intensity of the LFD test line as a percentage 
of the control line in the strips is shown in (c) for each. (* p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001). 
 
Paper-based Extraction 
For initial paper extraction experiments, solutions of influenza A (H1N1) RNA 
spiked into PBS were prepared at concentrations ranging from 10^10 copies of RNA per 
mL (cp/mL) down to 10^5 cp/mL, and a negative control containing no RNA. RNA 
solutions were mixed with the Glycoblue-containing lysis buffer, pipetted into the inlet 
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port of the extraction set-up (Figure 2), and filtered and washed through the paper 
membrane producing a visible blue film (Figure 8a inset). The complete extraction 
procedure with PES took approximately 18 minutes. The flow rates and times for all 
steps are shown in Figure 7. The extraction procedure with Polycarbonate resulted in 
significantly slower flow rates, and the experiment was discontinued after one hour 
(extraction still wasn’t complete by that point), since this amount of time would be 
unacceptable for point-of-care applications. Thus, we chose PES as our paper membrane 
and employed it for all further experiments. 
 
Figure 7.  Flow rates and times for extraction. Mean flow rate = 22.38 μl/min, SD = 3.8. 
Mean total extraction time = 17.87 min, SD = 3.28 (n=8).  
 
The RNA precipitate was eluted from the PES matrix and recovery yields were 
quantified using qRT-PCR (Figure 8c). Results from triplicate paper extraction 
experiments show good correlation between input and recovered RNA over 5-log of 
concentrations (r2=0.9989) with yields between 60% and 94%. Quantity values for RNA 
extracted through PES or via traditional centrifugation methods were compared (Figure 
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8c). RNA recovery yields through the PES membranes ranged from 66% to 109% of the 
centrifugation control yields. These results demonstrate that our paper extraction method, 
which is equipment-free and faster than traditional centrifugation extraction methods 
(~20 min versus ~35 min including drying times), results in comparable extraction yields 
over 5-log of RNA concentrations. 
 
 
Figure 8. Paper-based Extraction of Influenza A (H1N1) RNA. a) Schematic of the paper 
RNA extraction method. Nasopharyngeal swab samples are lysed in a Glycoblue-containing lysis 
buffer and filtered through our paper extraction set-up (scale bar = 10 mm). Co-precipitated RNA 
and Glycoblue result in a visible blue film (inset, scale bar = 1 mm). b) Paper extractions of 
H1N1 RNA standards and centrifuge control extraction yields quantified via qRT-PCR. Error 
bars: standard deviation, n=3. Percentage values indicate paper extraction yields compared to 
centrifuge control yields. Figure from: Rodriguez et al., Analytical Chemistry, 2015 
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Paper extraction and in situ RT-LAMP Assay 
Having previously demonstrated that LAMP reactions are not inhibited in the 
presence of PES, and can even take place completely within a PES matrix39 we next 
asked whether in situ amplification of the freshly-extracted RNA was possible within the 
same PES matrix. The optimized protocol for amplification in solution (Figure 4) served 
as a starting point for optimizing the paper-based RT-LAMP assay. Optimization 
experiments revealed that a higher MgSO4 concentration of 11 mM improved RT-LAMP 
performance in situ. All other assay reagent concentrations remained the same as the in 
solution reaction mix. As shown in Figure 10a, once the RNA was extracted onto the PES 
membrane, the 25 µL RT-LAMP reaction mix was added directly onto the RNA-
containing PES, and the full reaction volume was completely absorbed by the membrane. 
The soaked PES was then placed inside a 0.2 mL tube to prevent evaporation, and 
incubated in a 65ºC heat block for 23 minutes. During preliminary RT-LAMP in situ 
experiments, we found that the Glycoblue that co-precipitates with the RNA onto the PES 
caused a slight inhibition of the amplification (Figure 9a), and after careful optimization 
we determined that 23 minutes was the ideal reaction time for RT-LAMP in situ (Figure 
9b). After the 65ºC incubation, the soaked PES was then placed directly onto a lateral 
flow strip and 50 µL water was slowly dropped onto the PES to elute the amplified 
product onto the detection strip. In order to ensure that the water filtered through the PES 
before reaching the lateral flow strip, the PES and strip were placed between two acrylic 
sheets aligned with an inlet port, similar to the extraction set-up, except the lateral flow 
strip replaces the absorbent pad (Figure 3). The complete process from sample to answer 
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took approximately 45 min, including an 18-min average for the paper extraction, 
followed by 2 min drying, 23-min RT-LAMP reaction, and 2 min for detection on the 
lateral flow strips. 
 
Figure 9.  Effects of glycogen on RT-LAMP reaction. a) Real-time RT-LAMP amplification 
with increasing amounts of Glycoblue causing greater delays in amplification. b) Agarose gel 
electrophoresis of paper extracted RNA + RT-LAMP in situ products for 23 min at 65 oC. L= 
100bp DNA ladder, 10 = 10^10 cp/mL, 9 = 10^9 cp/mL, etc. NTC = no template control. 
 
Solutions of influenza A (H1N1) RNA spiked into PBS at concentrations ranging 
from 1010 down to 105 cp/mL and a negative control containing no RNA were extracted 
through the PES membrane just as in Figure 8 and amplified directly within the PES 
membrane via RT-LAMP in situ. The amplified products were eluted directly onto the 
lateral flow strips and representative lateral flow strips from three individual experiments 
are shown in Figure 10b and test line intensities from all three sets of strips were 
quantified and normalized to control line intensity (Figure 10c). Statistical analysis from 
the three experiments determined that detection of all but the lowest concentration (105 
cp/mL) were statistically significant when compared to the negative control. As shown in 
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Figure 10c, 105 cp/mL was amplified to detectable levels in two of the three experiments, 
albeit lightly in one of them. From these results, we can conclude that our lower limit of 
detection for RT-LAMP in situ is an order of magnitude higher (106 cp/mL) than RT-
LAMP in solution, however this would still theoretically cover over 90% of cases given 
the nasopharyngeal swab sample viral loads previously measured in a large group of 
patients35. 
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Figure 10.  RT-LAMP in situ with in-vitro transcribed H1N1 RNA standards. a) Method 
schematic of paper RNA extraction followed by in situ RT-LAMP and immediate downstream 
lateral flow detection. b) Representative lateral flow detection strips. 10 = 10^10 cp/mL, etc. NTC 
= no template control. c) Lateral flow detection strip test line intensities from three independent 
experiments are plotted as a percentage of control line intensities. (* p < 0.05, ** p < 0.01, *** p 
< 0.001, ns = not significant). Figure from: Rodriguez et al., Analytical Chemistry, 2015 
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Paper extraction, in situ RT-LAMP, and lateral flow detection of H1N1 RNA from 
clinical nasopharyngeal specimens 
To ensure compatibility of our paper extraction and in situ RT-LAMP assay with 
clinical specimens, 12 deidentified nasopharyngeal swab samples collected from patients 
that tested positive for H1N1 during the 2009 pandemic35 with a range of viral titers were 
selected for testing and labeled with letters A-L. Additionally, three H1N1-negative 
samples from patients exhibiting other respiratory illness at the time of specimen 
collection were chosen at random and tested by our assay (Figure 12). Prior laboratory 
testing indicated that one of the samples was Influenza B-positive, and two samples were 
Respiratory Syncytial Virus (RSV)-positive.  
Multiple aliquots were made of each clinical specimen and aliquots were stored at 
-80ºC. One aliquot from each positive patient sample was extracted via a QIAamp Viral 
RNA Mini Kit as a gold standard extraction method. We compared our paper extraction 
method to the Qiagen kit via qRT-PCR (Figure 11a). Our paper extraction yields ranged 
from 10% to 140% of Qiagen yields, exhibiting some variability that we speculate may 
be due to slight viral load variations across sample aliquots and possible effects of freeze-
thaw cycles. Nonetheless, results show good correlation between recovered RNA 
quantities from each method.     
 To be certain that our RT-LAMP assay would correctly amplify these H1N1 
positive clinical specimens, we first performed RT-LAMP reactions in solution using 
purified Qiagen-extracted RNA from each positive sample. All positive samples were 
amplified to detectable levels as shown by agarose gel electrophoresis (Figure 11b) and 
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lateral flow detection (Figure 11c).  Next, a fresh aliquot of each sample was extracted 
via our paper extraction method and amplified via our in situ RT-LAMP assay. A 
positive (109 cp/mL in vitro transcribed RNA) and negative (no RNA) sample were also 
extracted and amplified as controls. After a 23-minute incubation at 65ºC, the amplified 
products were eluted from the PES directly onto the lateral flow strips as shown in Figure 
10a, and strip test lines were quantified as a percentage of control lines (Figure 11d). 
None of the negative clinical samples tested positive by our assay, as shown in Figure 12, 
confirming our H1N1 strain-specificity. Ten of the 12 samples successfully tested 
positive via our paper extraction, in situ RT-LAMP, and LFD assay. The two samples 
that were not detected by our assay were the samples with the lowest viral titers (~2 x 106 
cp/mL) and also resulted in the lowest test line intensities in the Qiagen-extract RT-
LAMP in solution control assay (Figure 11c). This loss in sensitivity with clinical 
specimens as compared to our in vitro transcribed RNA standards tested in Figure 10 
could be a result of additional inhibitors in the biological specimens that may have 
remained in the paper extraction matrix and could potentially have interfered with the 
LAMP reaction. For example, saline is known to inhibit LAMP amplification in a dose-
dependent manner43, and it is possible that residual salt from the nasopharyngeal 
specimens were not entirely rinsed from the PES matrix during ethanol washes. 
Furthermore, incomplete inactivation of RNAses present in the specimens is also 
possible.  
 Despite this slight loss in sensitivity with clinical samples, our paper extraction 
and in situ RT-LAMP assay still offers a significant improvement in detection limit over 
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many commercially available rapid influenza diagnostic tests (RIDTs). In a recent study 
evaluating RIDT performance compared to qRT-PCR, results indicated that while qRT-
PCR detected viral loads as low as 103 cp/mL of influenza A, RIDTs typically showed 
negative results for viral loads less than 107 cp/mL44. According to the Center for Disease 
Control (CDC), sensitivities of rapid diagnostic tests for influenza are approximately 50-
70% when compared with RT-PCR, and specificities are approximately 90-95%32. Our 
group previously reported a study testing a large group of patient samples (n=119) 
collected from a clinical site in Boston during the same time period the samples tested 
here in Figure 11 were collected, and found that the rapid immunoassays (Xpect FluTM 
and BinaxNOWTM) were only 49% sensitive and 98% specific, with a positive predictive 
value of 97% and a negative predictive value of only 60%.16 Two other independent 
studies comparing influenza immunoassays have reported sensitivities as low as 39%45,46. 
During the 2009 H1N1 outbreak, a study conducted in New York City found that H1N1-
specific rapid diagnostics had sensitivities as low as 9.6% compared to viral culture47. 
Our lower detection limit of ~106 cp/mL is well within the clinically relevant range, and 
of the 12 known positive patient samples we tested, 10 (83%) were correctly identified as 
positive by our assay.  
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Figure 11. Clinical Nasopharyngeal Specimens. a) Paper extractions and QIAamp kit 
extractions of clinical specimens A-L. b) RT-LAMP assay performed in solution with Qiagen-
extracted purified RNA from clinical specimens A-L, gel electrophoresis of products. c) Lateral 
flow detection of amplified products; test line intensities plotted as percentage of control line 
intensities. d) Paper extraction of clinical specimens A-L followed by in situ RT-LAMP and 
lateral flow detection. + = positive control (10^9 cp/mL RNA standard), - = negative control (no 
RNA).  Figure from: Rodriguez et al., Analytical Chemistry, 2015 
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Figure 12. Lateral flow detection strips from negative clinical samples that were PES-
extracted and in situ RT-LAMP amplified. Three known H1N1-negative clinical samples from 
patients exhibiting symptoms of respiratory illness at the time of specimen collection were chosen 
at random. Prior laboratory testing indicated that sample 1 was Influenza B-positive, and samples 
2 and 3 were Respiratory Syncytial Virus (RSV)-positive. None were detected by our assay, 
demonstrating our H1N1 strain-specificity. 10^9 cp/mL H1N1 RNA and no RNA samples were 
run alongside the samples as positive and negative controls.  
Negative clinical sample 1 
Negative clinical sample 2 
Negative clinical sample 3 
Positive Control 
Negative Control 
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CHAPTER 3. MODULE INTEGRATION AND CHIP DESIGN 	  
3.1 Introduction 
 
 
Integrated molecular diagnostics to enable sample-to-answer nucleic acid testing 
have previously required sophisticated instrumentation to provide pressure driven fluid 
handling, cyclic thermal control, and optical assay detection. These requirements result in 
expensive equipment and costly disposables that are unsuitable for use in limited resource 
settings. Paper-based devices provide a cost-effective solution for point-of-care 
diagnostics7, and while a number of studies have reported on the success of individual 
NAAT steps (extraction, amplification, and detection) within paper matrices, the largest 
remaining challenge lies in the integration of these separate paper-based modules. In this 
chapter, we sought to integrate all three modules onto a single paperfluidic chip in a 
modular, foldable system (Figure 13) that allows for fully integrated fluidic handling 
from sample to answer. The chip is made entirely of paper and adhesive sheets, making it 
low-cost, portable, and disposable, offering the potential for use in very remote settings. 
To date, only one other device has been reported recently that combines paper-
based extraction, amplification and detection steps17, which consists of a magnetic sliding 
strip to run each step serially. While this device does encompass a fully integrated NAAT 
system, it relies on a UV light source and imaging for endpoint detection, requiring 
equipment that may not be readily available in remote low-resource settings. 
Furthermore, this device has only been shown to detect E. coli DNA that was spiked into 
plasma, rather than extracting DNA from clinical specimens. Here, we demonstrate 
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detection of a target nucleic acid analyte directly from crude clinical samples without the 
need for pumps or detection equipment of any kind. 
This novel diagnostic platform could overcome many barriers currently faced in 
limited-resource settings and increase access to infectious disease screening and early 
detection for patients, improving their quality of life and reducing mortality from late 
detection.  
 
3.2 Materials and Methods 
 
Paperfluidic Chip Fabrication 
Standard letter size self-adhesive laminating sheets (Fellowes product # 5221502) 
served as the base material for building our paperfluidic chip, providing a hydrophobic 
(tape) barrier surrounding the paper components that is low-cost and optically transparent 
to enable our visual readout. We created blueprint drawings for the adhesive base of the 
chip (Figure 13b) using computer-aided design software (AutoCAD), and cut the 
adhesive sheets accordingly using an electronic craft cutting tool (Graphtec Craft Robo 
Pro S with Graphtec Studio software) using a standard blade (CB09U) and the following 
settings - cut force: 27, speed: 7 cm/s, acceleration: 1. The blueprint drawings include 
perforations in the adhesive sheets that were specifically designed to enable easily folding 
and ripping as needed during chip fabrication and operation, such that the integrity of the 
chip would remain uncompromised. The cut adhesive sheets were peeled from the 
protective backing and placed adhesive side-up on the benchtop as shown schematically 
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in Figure 14, step i. Polyethersulfone (PES) filter paper (Millipore, cat# GPWP04700) 
was cut into 0.375-inch diameter discs using a 3/8” craft hole punch (EK Tools, 54-
10061). A single 0.375-inch diameter PES disc is manually placed directly over the 0.3 
inch diameter hole in the adhesive sheet, and the top tab is folded down along the 
perforation over the PES (Figure 14, step ii) to create the sample port (Figure 14, step iii). 
Next, the bottom tab is folded up along the perforation to create a toehold for what will 
become the sample port cover film to prevent evaporation during the LAMP heat step 
(Figure 14, step iv). The 0.3 inch diameter circle of tape that had been cut out of the 
adhesive sheet to make the sample port is peeled off the protective backing where it 
stayed behind and is manually placed adhesive side-down onto the adhesive sheet 2 
inches down from the center of the sample port (Figure 14, step v). This will align with 
the sample port when the cover film is placed during LAMP and prevent the DNA and/or 
PES membrane from sticking to the adhesive cover film.  
Cellulose blotting paper (Whatman GB003, cat# 09-301-400) was cut using a 30W 
Epilog Zing laser cutter (speed=70%, power=28%, frequency=200) to make absorbent 
pads shaped as 2.5-inch long sectors that extend radially from 0.375 inch at the base of 
the sample port to an ultimate width of 0.75 inch (drawn in SolidWorks, Waltham, MA). 
The absorbent pad is manually aligned and placed over the sample port extending 
towards the left side of the chip as shown in Figure 14, step vi. The lower middle section 
of the chip is then folded over the centerline perforation over the absorbent pad as shown 
in Figure 14, steps vii-viii to create a hydrophobic (tape) barrier between the absorbent 
pad and the LFD strip. The LFD strip is then manually aligned with the sample port 
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center and placed down extending over the right side of the chip as shown in Figure 14, 
step ix. Next, the bottom two remaining sections of the adhesive sheet are folded up over 
the perforations to seal the chip from the bottom (Figure 14, steps x-xi). The fabrication 
is now complete, and the chip is then flipped over so that the PES membrane sample port 
is right side-up and ready for use (Figure 14, step xii).  
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Figure 13. Paperfluidic Molecular Diagnostic Chip Prototype. A) Image of paperfluidic chip. 
Scale bar = 1 inch. B) Blueprint drawings and dimensions for the adhesive base of the chip. 
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Figure 14. Schematic of chip fabrication steps: i. The cut adhesive sheets are peeled from the 
protective backing and placed adhesive side-up on the benchtop (the white area is adhesive sheet, 
the dark grey areas are holes that have been cut out of the adhesive sheet); ii. A 0.375 inch 
diameter PES disc is manually placed directly over the 0.3 inch diameter hole in the adhesive 
sheet, and the top tab is folded down along the perforation over the PES; iii. The sample port is 
now created (the light grey color indicates areas where the adhesive sheet has been folded over 
onto itself, rendering the area non-adhesive); iv. The bottom tab is folded up along the perforation 
to create a toehold for what will become the sample port cover film to prevent evaporation during 
the LAMP heat step; v. The 0.3 inch diameter circle of tape that had been cut out of the adhesive 
sheet to make the sample port is peeled off the protective backing where it stayed behind and is 
manually placed adhesive side-down onto the adhesive sheet 2 inches down from the center of the 
sample port. This will align with the sample port when the cover film is placed during LAMP and 
prevent the DNA and/or PES membrane from sticking to the adhesive cover film; vi. The 
absorbent pad is manually aligned and placed over the sample port extending towards the left side 
of the chip; vii-viii. The lower middle section of the chip is then folded over the centerline 
perforation over the absorbent pad to create a hydrophobic (tape) barrier between the absorbent 
pad and the LFD strip; ix. The LFD strip is then manually aligned with the sample port center and 
placed down extending over the right side of the chip; x-xi. The bottom two remaining sections of 
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the adhesive sheet are folded up over the perforations to seal the chip from the bottom; xii. The 
fabrication is now complete, and the chip is then flipped over so that the PES membrane sample 
port is right side-up and ready for use.  
 
3.3 Results and Discussion 
 
Fluidic Demonstration of Chip Operation 
A lysed sample, demonstrated here using 100 µL of blue dye, is placed onto the sample 
port of the paperfluidic chip using a pipette or dropper (Figure 16i). The prevailing 
capillary forces generated by the absorbent pad directly underneath the sample port 
quickly wick the liquid waste through the PES membrane and away from the sample port 
(Figure 16ii). A hydrophobic (tape) barrier between the absorbent pad and the LFD strip 
prevents the liquid waste from wicking through to the LFD strip (see side view schematic 
in Figure 15). Any solid phase within the sample, most importantly the precipitated DNA, 
will remain on the sample port surface. Next, a first wash of 70% ethanol, demonstrated 
here using 200 µL of yellow dye, is filtered through the sample port (Figure 16iii-iv). The 
wash buffer will wick through to the absorbent pad, removing most impurities like cell 
debris, proteins, and salts and leaving behind the purified precipitated DNA. Because 
ethanol can inhibit the subsequent LAMP reaction, it is important to completely dry the 
sample port. To that end, a final wash of 100% ethanol, demonstrated here using 100 µL 
water, is filtered through the sample port (Figure 16v), leaving just the purified DNA 
precipitates on the PES membrane (Figure 16vi). 
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Figure 15. Paperfluidic Chip Sideview Schematic. a) Chip prior to use. The absorbent pad 
(grey) is in direct contact with the PES sample port (blue), thus any liquid will wick into the 
absorbent pad and towards the left. Once extraction and wash steps are complete, the chip is 
ripped at the perforation in the tape, and the entire left side of the chip is removed. (Note the now 
wet absorbent pad delaminates from the tape, allowing complete removal). b) After the absorbent 
pad has been removed, the PES and LFD strip (LFS, pink) are separated by a hydrophobic tape 
barrier. c) After LAMP, the tape barrier is removed (by ripping at a perforation) and the PES is 
left in direct contact with the LFD strip, allowing eluted amplified products to wick directly onto 
the strip.  
 
 The waste absorbent pad is no longer needed at this point and can be discarded by 
ripping off the left side of the chip at the designated perforation (Figure 16vii). Next, 12.5 
µL of the LAMP reaction mix is placed directly onto the sample port where the purified 
DNA remains, and the bottom tab of the chip is folded up over the designated perforation 
to act as a cover film for the sample port and prevent evaporation during the heat step 
(Figure 16viii). The chip is then placed face-down onto a heat block or hot plate set to 
63ºC for 30 min (not shown). Preliminary experiments evaluating evaporative fluid loss 
were performed by weighing the chip before and after the 30min heat step. An average 
loss of 5.6% was calculated. On-chip LAMP experiments will be required to reveal 
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whether or not this loss will affect amplification.  
After the heat incubation, the cover film is peeled back using the toehold to 
expose the sample port on top, and peeled under the chip to expose the sample port outlet 
on the bottom, thereby removing the hydrophobic (tape) barrier between the sample port 
and the LFD strip. The PES membrane is now in direct contact with the LFD strip and the 
amplified products are then eluted onto the strip by adding 50 µL water to the sample 
port (Figure 16ix). The eluted products wick through the LFD strip towards the absorbent 
pad on the right. As the liquid wicks through the conjugate pad, the streptavidin-
conjugated gold nanoparticles bind the biotin probes on the LB primers within the 
amplicons. As the liquid continues to wick over the detection zone, amplicons that also 
contain the FITC probe on the LF primers will aggregate at the anti-FITC test line. Any 
excess streptavidin-conjugated gold nanoparticles will continue to wick through the LFD 
strip and bind the biotin control line, which confirms that the strip functioned properly. 
Here, as this was just a demonstration using water, the test result is obviously negative, 
thus only the control line appears on the strip (Figure 16x). 
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Figure 16. Fluidic Demonstration of Chip Operation. i) A lysed sample, demonstrated here 
using 100 mL of blue dye, is placed onto the sample port of the paperfluidic chip using a pipette 
or dropper . ii) The prevailing capillary forces generated by the absorbent pad directly underneath 
the sample port quickly wick the liquid waste through the PES membrane and away from the 
sample port leaving the solid phase behind. iii) A first wash of 70% ethanol, demonstrated here 
using 200 mL of yellow dye, is filtered through the sample port. iv) The wash buffer will wick 
through to the absorbent pad, removing impurities and leaving behind the purified precipitated 
DNA. v-vi) A final wash of 100% ethanol, demonstrated here using 100 mL water, is filtered 
through the sample port, leaving just the purified DNA on the PES membrane. vii) The waste 
absorbent pad is discarded by ripping off the left side of the chip at the designated perforation. 
viii) The LAMP reaction mix is placed directly onto the sample port where the purified DNA 
remains, and the bottom tab of the chip is folded up over the designated perforation to act as a 
cover film for the sample port and prevent evaporation during the heat step. ix) After the heat 
incubation for LAMP, the cover film is peeled back using the toehold to expose the sample port 
on top, and peeled under the chip to expose the sample port outlet on the bottom, thereby 
removing the hydrophobic (tape) barrier between the sample port and the LFD strip. The PES 
membrane is now in direct contact with the LFD strip and the amplified products are then eluted 
onto the strip by adding 50 mL water to the sample port. x) The eluted products wick through the 
LFD strip towards the right. 
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CHAPTER 4. HUMAN PAPILLOMAVIRUS DNA TESTING ON-CHIP 	  
4.1 Introduction 
 
To showcase the full sample-to-answer functionality of the integrated paperfluidic 
chip, we chose to design a test for cervical cancer, a disease that disproportionately 
affects the developing world where early detection is made difficult by a lack of 
screening methods suitable for these low-resource settings, and for which a rapid, low-
cost, point-of-care molecular test of this nature is greatly needed. Each year, over half a 
million new cases of cervical cancer and over a quarter of a million deaths caused by 
cervical cancer occur worldwide48,49.  Despite its alarming global mortality, cervical 
cancer is highly preventable and easily treated through early detection and removal of 
precancerous lesions48,50. Unfortunately, cervical cancer is most prevalent in areas where 
no effective screening programs have been established. From a total of 528,000 new 
cases worldwide in 2012, 445,000 cases (84%) occurred in the developing world49, 
where, according to the World Health Organization (WHO), less than 5% of women have 
access to screening even once in their lifetime51,52. 
  The traditional method to detect cervical cancer is the Pap smear, where trained 
pathologists analyze cervical smears under a microscope and determine if there is 
evidence of abnormal cells. Although cytology-based screening has dramatically reduced 
the incidence and mortality of cervical cancer in many developed countries, it is a 
qualitative process that suffers from very low sensitivity (as low as 53%)53, and 
successful cytological screening programs have been difficult to implement and sustain in 
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remote and low-income settings because they are resource-intensive and require highly 
trained personnel54. Moreover, many developing regions lack the necessary infrastructure 
to transport Pap smears to and from a laboratory for processing and interpretation in a 
timely manner, thus requiring up to three patient visits to the clinic for screening, 
communication of results, and treatment. The delay in getting results back to patients is 
known to be a particularly significant barrier to screening, because large numbers of 
women won’t return for results50.  Efforts to reduce global cervical cancer incidence and 
mortality need to more effectively target developing regions via alternative methods that 
are less costly, less dependent on existing laboratory infrastructure and trained 
professionals, and capable of rapid, accurate diagnosis at POC. 
Visual inspection with acetic acid (VIA) is a rapid and inexpensive detection 
method that has been promoted globally as a reasonable alternative to the Pap smear, but 
studies have revealed unacceptably low sensitivity and specificity, resulting in very high 
rates of false negative and false positive results55,56. Moreover, VIA is tissue-based, and 
does not provide molecular information on the presence of the etiological agent of 
cervical cancer, human papillomavirus (HPV). 
HPV is a common sexually transmitted infection, which in the majority of cases is 
transient, asymptomatic, and clinically insignificant. In some women, however, the 
infection becomes persistent and may lead to the development of cervical cancer. Over 
99% of cervical cancer cases are caused by HPV57, more than half of which are caused by 
the HPV 16 subtype58. Given the limitations of cytology, much work has been focused on 
molecular diagnostics for cervical cancer through HPV DNA testing. These methods 
	  	  
54 
typically have very high sensitivity (>96-100%) and specificity (>90-100%)53, and are 
typically based on the chemiluminescent detection of RNA probes hybridizing to target 
DNA, like the Qiagen Digene Hybrid Capture II (HC2) test, the first HPV test approved 
by the FDA. This assay is performed in a laboratory with a plate reader and can take 6-7 
hours. Other molecular diagnostics for HPV detection include careHPV, a lower cost 
version of the Digene test developed by PATH (Seattle, WA) and Qiagen (Valencia, CA), 
Hologic’s Cervista (Marlborough, MA), and Roche’s cobasHPV test (Basel, 
Switzerland), which use similar hybridization technology59,60. A landmark study in rural 
India showed that a single round of HPV testing was associated with a significant 
reduction in the numbers of advanced cervical cancers and deaths from cervical cancer 
over time compared to cytology or VIA61. While these results validate the use of HPV 
DNA testing, a significant drawback is the high cost and the need for sophisticated 
laboratory equipment. Furthermore, current HPV DNA tests still require highly trained 
laboratory personnel and incur turnaround times of hours to days, depending on how far 
the sample has to travel to a central laboratory62. 
Translating the molecular testing process to the POC can minimize these 
limitations by providing results faster, on the order of minutes, allowing doctors to 
diagnose, advise and potentially treat patients in the same visit. Asymptomatic patients 
positive for high-risk HPV strains like 16 could be screened more closely, thus allocating 
precious resources to those most at risk. A POC diagnostic device could be taken to 
remote settings beyond a standard clinic or laboratory, eliminating transport turnaround 
time. Additionally, a user-friendly, self-contained diagnostic device, with a simple visual 
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readout similar to an at-home pregnancy test, could eliminate the need for highly trained 
specialists and require only minimal training of any community health worker. 
In this chapter, we developed a fully integrated, on-chip, sample-to-answer 
NAAT assay for the detection of HPV 16 DNA directly from patient cervical specimens 
in under an hour. 
 
4.2 Materials and Methods 
 
HPV 16 Cloned DNA Standards 
HPV 16 DNA standards were generated by cloning the E7 gene for HPV 16 into 
the pGEM-T Easy Vector (Promega, Madison, WI). The E7 gene was PCR amplified 
from HPV-16 transformed cell DNA (Advanced Biotechnologies, Inc, Eldersburg, MD) 
with gene-specific forward and reverse cloning primers (Table 3) containing restriction 
endonuclease sequences SpeI and AatII, respectively, using the standard Taq Polymerase 
protocol (New England Biolabs, Ipswich, MA). The PCR product was purified via phenol 
chloroform extraction and ethanol precipitation. The cleaned PCR product was digested 
overnight with SpeI and AatII restriction endonucleases (New England Biolabs, Ipswich, 
MA). The relevant band was gel extracted and ligated to the pGEM vector and 
transformed into Top 10 cells from Life Technologies (Grand Island, NY). Plasmid DNA 
was extracted using a Mini Prep Kit (Qiagen, Valencia, CA) and sequenced (GeneWiz, 
Inc, Cambridge, MA) to confirm proper E7 insert. A Midi Prep Kit (Qiagen, Valencia, 
CA) was used to generate large-scale plasmid stocks of the correctly sequenced DNA. 
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The plasmid stocks were linearized with ZraI restriction endonuclease (New England 
Biolabs, Ipswich, MA). The correct size fragment was gel extracted using the QIAquick 
Extraction Kit (Qiagen, Valencia, CA), phenol chloroformed, and ethanol precipitated. 
The concentration of the purified DNA was determined by measuring the OD260 with 
the NanoDrop ND-2000c apparatus (Thermo Scientific, Waltham, MA). The DNA copy 
number was calculated and 1 mL aliquots were made and stored at -20°C. 
 
Clinical Cervical Specimens 
The cervical specimens were accrued from the BIDMC cytology laboratory, on 
already tested and to be discarded specimens. The IRB approval and patient consent for 
research use of these de-identified and discarded specimens was waived by the BIDMC 
Institutional Review Board.  The specimens were obtained in PreservCyt® solution.  
Testing was done on an FDA approved plaform (Cervista; hrHPV), which evaluates 14 of 
the most common high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
66, and 68) using Invader Chemistry. Any patient health identifying information was 
completely removed, and the specimens were labeled with a sample number and as HPV 
positive or negative only before they were transferred to the Klapperich Laboratory.  
Samples were then transferred to 50 mL conical tubes and centrifuged for 10 min at 4000 
RPM. The supernatant was removed and the cell pellet was washed with 3 mL PBS, 
vortexed and centrifuged for 10 min at 4000 RPM. This was repeated twice, leaving a 
cell pellet that was resuspended in 3 mL PBS and divided into (3) 1 mL aliquots. Each 1 
mL aliquot was centrifuged for 5 min at 13000 RPM. The supernatant was removed and 
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pellets were frozen at -80°C for long-term storage. Prior to use, pellets were resuspended 
in 1 mL PBS, subdivided into 200 µL aliquots, centrifuged for 10 min at 13000 RPM, 
and the supernatant was removed, resulting in single-use pellets for experiments. It is 
important to note that these centrifugation steps were required here because the patient 
samples we received as part of our IRB-approved study were cervical tissue specimens 
fixed in large volumes of ethanol-containing PreservCyt® solution, which is unsuitable 
for direct use in a POC device. In a real-world setting, a fresh or dried cervical swab 
would be placed directly into our lysis buffer, thereby eliminating these extra 
centrifugation steps. 
For gold standard extraction experiments, DNA was extracted from a single-use 
pellet of each specimen using the DNeasy Blood & Tissue Kit (QIAGEN) and eluted into 
a final volume of 200 µL. 
 
qPCR 
To ascertain the DNA extraction yields, 5 µL of extracted DNA was amplified via 
quantitative PCR (qPCR).  Using the Surestart Taq DNA polymerase (Agilent, Santa 
Clara, CA), real-time PCR was performed on an Applied Biosystems 7500 thermocyler 
under the following conditions: 10 min at 95°C for polymerase activation, followed by 30 
cycles of 30 sec at 95°C, 15 sec at 55°C for primer annealing, and 90 sec at 60°C for 
amplification. The 25 µL reaction mixture contained 1X TaqMan buffer, 3.5mM MgCl2, 
8% DMSO, 200uM dNTPs, 200nM primers and TaqMan probes (Table 3), 0.1X Rox 
Reference Dye, 0.625U Taq DNA polymerase, and 5 μL of sample or standard DNA. For 
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clinical specimen gold standard extraction experiments, a multiplexed HPV 16 and 
RNaseP qPCR assay was run following the same reaction conditions where RNaseP 
served as a DNA control to confirm that each clinical specimen did in fact contain cells 
and that the Qiagen extractions were performed properly. If a clinical sample was 
negative for RNaseP (cycle threshold value > 30), the sample was deemed invalid and 
was not used for further experiments. 
In each qPCR run, a cycle threshold value versus DNA concentration standard 
curve was generated from a dilution series of our cloned HPV 16 DNA standards.  For 
each patient sample, the effective viral DNA concentration was quantitated via standard 
curve interpolations. 
 
Isothermal Loop-Mediated Amplification Assay  
An isothermal loop-mediated amplification (LAMP) assay was developed for 
rapid amplification and detection of the HPV 16 E7 gene using primer sequences 
previously designed by Luo et al.63 listed in Table 3. The assay was first optimized in 
tube, and then translated to a chip format. The assay takes place in situ, in a PES 
membrane in the sample inlet port, as previously described by our group36,39. The in-tube 
reaction was carried out in a final volume of 25 µL with 1 µL of the DNA sample, 1x 
Isothermal Amplification Buffer (New England Biolabs), 8 U large fragment Bst 2.0 
DNA polymerase, 0.8 M Betaine, 1 mM dNTPs, 5 pmol each of forward and reverse 
outer primers (F3 and B3), 20 pmol each of forward and reverse loop primers (LF and 
LB), and 40 pmol each of forward and reverse inner primers (FIP and BIP). The on-chip 
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LAMP reaction recipe was identical but was carried out in a final volume of 12.5 µL. 
Fresh, single-use aliquots of each reagent were used each time. The reaction was run for 
30 minutes at 63ºC. Forward and reverse loop primers (LF and LB) were tagged with 
Fluorescein isothiocyanate (FITC) and biotin, respectively, to enable immediate 
downstream detection of the amplified products on immunochromatographic, lateral flow 
detection (LFD) test strips (Ustar Biotechnologies, Hangzhou, China) consisting of 
streptavidin-conjugated gold nanoparticles, an anti-FITC test line, and a biotin (anti-
streptavidin) flow control line. 
 For in-tube LAMP assay experiments, the amplified products were analyzed by 
2% agarose gel electrophoresis. The specificity of the products was confirmed by 
restriction enzyme digestion with the PvuII restriction endonuclease (New England 
Biolabs) with a single cutting site within the FIP region. Following digestion at 37°C 
overnight, the digested products were analyzed by 2% agarose gel electrophoresis and by 
10% acrylamide gel electrophoresis for higher resolution analysis. 
 LFD strips were imaged using an iPhone 5 camera (Apple). LFD test line and 
control line intensities were quantified using the Gel Analysis feature in ImageJ (National 
Institutes of Health) and analyzed by dividing the intensity of the test line by the intensity 
of the control line to obtain the percentage of control intensity for each sample. The 
resulting intensities were plotted as median with range. Unpaired, two-tailed Student’s T-
tests were used to determine the significance of each sample readout compared to the 
experimental negative control sample readout. 
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Primer Name Sequence 
PCR_Fwd AGC TCA GAG GAG GAG GAT GAA 
PCR_Rev GGT TAC AAT ATT GTA ATG GGC TC 
PCR_Probe /56-FAM/CC AGC TGG ACA AGC AGA ACC GG/3IABkFQ/ 
SpeI_Fwd* CCGAACTAGTatgcatggagatacacctacattgca 
AatII_Rev* GATTGACGTCttatggtttctgagaacagatggggc 
LAMP_F3 AGACAACTGATCTCTACTGTT 
LAMP_B3 CTTCCAAAGTACGAATGTCTAC 
LAMP_FIP TTCTGCTTGTCCAGCTGGACGCAATTAAATGACAGCTCAGAG 
LAMP_BIP CCGGACAGAGCCCATTACAATGTGTGTGCTTTGTACGCA 
LAMP_LF FITC-CATCTATTTCATCCTCCTC 
LAMP_LB Biotin- TGCAAGTGTGACTCTACGCT   
*cloning primers 
Table 3. HPV 16 Primer Sequences 
 
Integrated On-Chip Assay 
DNA Extraction and Purification 
A single-step cell lysis and DNA extraction recipe was developed based on the 
chaotropic lysis and alcohol precipitation methods of Boom et al.64 and Linnes et al.25 A 
single-use pellet of each clinical cervical specimen (or 6 µL of cloned HPV16 DNA 
during preliminary experiments) was resuspended in a lysis buffer containing 3M 
guanidinium thiocyanate, 300 mM sodium chloride, 35% v/v 1-butanol (Sigma Aldrich, 
St. Louis, MO), and 3 µL of 15 mg/mL Glycoblue coprecipitant (Life Technologies, 
Grand Island, NY) in a total volume of 100 µL. This mixture was pipetted onto the 
sample port of the paperfluidic chip. The liquid phase wicks through the absorbent pad 
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directly underneath the PES membrane by capillary forces, leaving the precipitated DNA-
Glycoblue solid phase. A series of ethanol washes (200 µL of 70% ethanol, followed by 
100 µL of 100% ethanol) were then pipetted through the sample port, removing 
impurities while leaving the purified DNA-glycogen precipitate on the PES membrane. 
The left side of the chip containing the soiled absorbent pad was then ripped along the 
perforation and discarded. The rest of the chip is left on the benchtop for at least 2 
minutes to allow for complete drying of the ethanol prior to addition of the LAMP 
reaction mix. 
 
Isothermal Amplification 
A 12.5 µL LAMP reaction mix was pipetted directly onto the sample port and was 
fully absorbed by the PES, presumably dissociating the DNA-Glycoblue complexes. The 
bottom tab of the chip is then folded up along the perforation and pressed down to seal 
over the absorbent pad and serves as a cover film to prevent evaporation during the 
incubation period for LAMP. The chip is then placed face-down on a 63ºC heat block or 
hot plate for 30 min.  
 
Lateral Flow Detection 
Following the LAMP incubation, the cover film was peeled back using the 
toehold tab to expose the sample port on top, and peeled under the chip to expose the 
sample port outlet on the bottom, thereby removing the hydrophobic (tape) barrier 
between the sample port and the LFD strip (see side view schematic in Figure 15). 50 µL 
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of nuclease free water was then pipetted onto the sample port, which filtered through the 
PES and wicked directly onto the LFD strip for immediate detection of amplified 
products. 
 
4.3 Results and Discussion 
 
 
HPV 16 E7 LAMP Assay 
The HPV 16 E7 LAMP assay was first optimized in-tube using our cloned 
HPV16 DNA standards. We ran the optimized AMP assay using serial dilutions of our 
DNA standards and found that our lower limit of detection was 10^4 total copies as 
confirmed by agarose gel electrophoresis (Figure 17a) and LFD strips (Figure 17b). The 
LFD strips enable immediate detection of amplified products with the naked eye. Test 
line intensities were quantified as a percentage of control line intensities and results from 
three independent experiments are plotted in Figure 17c. DNA quantities down to 10^4 
total copies show a clear visible test line that is statistically different from the negative 
control. While 10^3 DNA copies were not amplified to detectable levels, the HPV 
literature has shown that a viral load below 10^4 copies is not indicative of cervical 
cancer progression65,66.  
We included a no template control (NTC), and a nonspecific DNA control (10^6 
total copies of HPV 18 DNA), both of which were negative on both the gel and LFD 
strips, demonstrating primer specificity. Additionally, we ran our LAMP assay on Qiagen 
kit-extracted DNA from a patient sample that tested positive for HPV 16 and from a 
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clinical sample that tested negative for HPV 16. It is important to note that these samples 
contain large amounts of human DNA and potentially other viral genomes. Our LAMP 
assay correctly identified these patient samples as positive and negative, respectively, 
thus further confirming the specificity of our LAMP assay. 
 One disadvantage to the LAMP method is the possibility for interaction and self-
priming of the oligonucleotides during the reaction. This phenomenon has been widely 
reported in the literature67-70, and is usually circumvented by optimization of assay 
conditions and setting an assay cutoff time far before these events are likely to occur. 
Nonetheless, because our ultimate assay detection method is based on primer-tagged 
probes, it was important to ensure that a positive result on the LFD strip correlated to a 
LAMP product specific to our target sequence. To this end, the amplified products were 
digested with the PvuII restriction endonuclease and analyzed by 2% agarose gel 
electrophoresis (Figure 17d) and at higher resolution by 10% acrylamide gel 
electrophoresis (Figure 17e). The HPV 16 E7 gene sequence contains a single PvuII 
cutting site within the FIP region, and positive product digests were in agreement with 
the expected band sizes71 (47, 53, 72, 80, 116, 117, 124, 130, and 173 bp, with main 
repeating units of 53 and 130 bp), while the negative product digests showed nothing on a 
low-resolution agarose gel (Figure 17d) and showed irregular band patterns inconsistent 
with expected band sizes on a high-resolution acrylamide gel (Figure 17e).  
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Figure 17. HPV 16 E7 LAMP Assay in solution. a) 2% Agarose gel electrophoresis of LAMP 
products. L= 100bp DNA Ladder, 6 = 10^6 DNA copies, 5 = 10^5 DNA copies, 4 = 10^4 DNA 
copies, 3 = 10^3 DNA copies, NTC = no template control, 18 = 10^6 copies of HPV 18 DNA, 
POS = DNA extracted from an HPV16-positive patient sample, NEG = DNA extracted from an 
HPV16-negative patient sample. b) Representative lateral flow strips from three independent 
experiments show detection of LAMP products. Top line is the test line, bottom line is the flow 
strip control line.  c) Test line intensity as percentage of control line intensity for three 
experiments is plotted as median with range and statistically compared to NTC control (*** p < 
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0.001, **** p < 0.0001, ns = not significant). d) 2% Agarose gel electrophoresis of PvuII-
digested LAMP products. L1= 100bp DNA Ladder, L2 = PBR322 DNA-Msp1-digest Ladder. e) 
10% Acrylamide gel electrophoresis of Pvu-II digested LAMP products. 
 
 Having confirmed the lower detection limit and specificity of our HPV16 LAMP 
assay in-tube, we then tested our LAMP assay in situ, directly within a paper matrix 
containing freshly extracted HPV16 DNA. Our group has previously reported on the 
successful isothermal amplification of nucleic acids within PES matrices39, as well as on 
the successful extraction of nucleic acids in PES followed by in situ amplification36. To 
test our HPV16 LAMP assay in situ, first we extracted solutions of known concentrations 
of HPV16 DNA mixed with our Glycoblue-containing lysis buffer through a PES 
membrane using an acrylic extraction setup previously described36. The extracted DNA 
was eluted from the PES matrices and quantified via qPCR (Figure 18a). Recovery yields 
were between 46% and 88% of centrifugation controls, consistent with what our group 
had previously reported for RNA. Next, HPV16 DNA solutions were again extracted 
through a PES membrane as described above, but this time instead of eluting the 
extracted DNA from the PES, 12.5 µL of our LAMP reaction mix was pipetted directly 
onto the PES membrane where it was fully absorbed. The PES disc was placed inside of a 
tube and incubated at 63ºC for 30min. The amplified products were eluted via 
centrifugation from the PES membrane and analyzed via 2% agarose gel electrophoresis. 
As shown in Figure 18b, our LAMP assay successfully amplified as low as 10^4 total 
copies of HPV 16 DNA in situ.  
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Figure 18. HPV 16 PES Extractions and in situ LAMP 
 
Integrated On-Chip Assay with cloned HPV 16 DNA standards 
Once we confirmed adequate extraction and amplification of HPV 16 DNA in a 
PES membrane, we then integrated each assay component onto our paperfluidic chip, 
following the step-by-step protocol outlined in Figure 16 and using solutions of known 
concentrations of our cloned HPV 16 DNA standards. On-chip extractions took 
approximately 10-15 minutes, as flow was significantly slowed after a visible blue DNA-
Glycoblue film developed on the PES membrane following the initial sample filtration 
(images shown in Figure 19a). We also found that we needed to dispense the 100 µL 
sample only 50 µL at a time due to the lower surface tension of our lysis buffer 
containing 35% butanol, otherwise the liquid would spill over the sample port. Likewise, 
our 70% ethanol wash was dispensed 25 µL at a time, and the 100% ethanol wash was 
dispensed 10 µL at a time. Following the extraction and ripping off of the waste pad, the 
visible Glycoblue-containing dry precipitates were observed only on the PES membrane, 
and not significantly on the absorbent pad underneath, suggesting good recovery (Figure 
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19b). The LAMP reaction mix was then added directly to the dry sample port and 
immediate mixing with the Glycoblue-containing precipitates was observed. Following 
the 30 min heat step, the cover film tab was peeled back and the LAMP reaction liquid 
was visibly still present on the sample port, suggesting minimal evaporation. Following 
addition of 50 µL water to the sample port, elution onto the LFD strip began 
immediately, and test results were visible within 2 min. 
 
Figure 19. On-chip extraction images demonstrating a) visible blue DNA-Glycoblue film 
forming on PES and b) hardly any blue visible on absorbent pad underneath. 
 
  
As shown in Figure 20a, our integrated on-chip assay resulted in clear, positive 
LFD readouts from starting material as low as 10^4 copies of HPV 16 DNA, and a clear 
negative readout for the negative control. The statistical analysis from three independent 
experiments is shown in Figure 20b. 
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Figure 20. Integrated on-chip assay with cloned HPV 16 DNA standards. a) Representative 
lateral flow strips from three independent on-chip experiments show detection of LAMP products 
from 1E4 to 1E6 DNA copies, NTC = no template control. Left line is the test line, right line is 
the flow strip control line. b) Test line intensity as percentage of control line intensity for three 
experiments is plotted as median with range and statistically compared to NTC control (** p < 
0.01, *** p < 0.001, **** p < 0.0001). 
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Integrated On-Chip Assay with Clinical Cervical Specimens 
DNA from cervical tissue sample pellets was extracted via the gold standard 
Qiagen DNeasy Tissue Kit. Each sample extraction was analyzed by qPCR for HPV16 
E7 and RNaseP DNA. RNaseP serves as a human gene internal control to ensure that the 
cervical swab sample contained cervical cells and that DNA was properly extracted. Any 
samples that tested negative for RNaseP by qPCR were considered “invalid” and were 
not used in further experiments. Five HPV 16 positive and five HPV 16 negative samples 
(Figure 21 table) were selected for on-chip testing to demonstrate proof-of-concept 
clinical utility of our paperfluidic chip. 
 A single-use pellet from each sample A-J was resuspended in 100 μL lysis buffer, 
vortexed thoroughly, and pipetted onto the sample port of the chip. During preliminary 
experiments, significant accumulation of debris and salts from the lysed samples left a 
visible grainy film on the PES membrane, which greatly inhibited the subsequent LAMP 
reaction. This prompted an increase from 100 to 200 µL of our 70% ethanol washes, 
which did not entirely remove the residue in all cases, but significantly improved LAMP 
performance nonetheless.  
All 5 positive samples resulted in clear, positive LFD results as seen in Figure 21 
strips A-E. Of the 5 negative samples, 3 resulted in a negative LFD result (strips G, I, J), 
but 2 exhibited faint test lines (F, H) resulting in a false positive result. Test line 
intensities were quantified and divided by the intensity of the control line to obtain the 
percentage of control intensity for each sample, and plotted in Figure 21. All positive 
samples resulted in test line intensities of at least 46%, while the highest false positive 
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result had a test line intensity of 22%. It may be possible in the future to previously 
determine a cut-off intensity value below which one would read the result as negative (for 
example here we could set a theoretical cutoff of 30%). However, this would introduce 
user-to-user variability and would require a camera phone or other imaging equipment for 
a quantitative intensity readout. Thus, this approach would be less ideal, and instead we 
will focus future efforts on optimization of the assay to minimize false positive results. 
As mentioned above, interaction and self-priming of two or more of the six 
primers involved in LAMP is a widely recognized issue that may be the cause of our false 
positive results. Considering our LFD strip detection method, moving forward we suspect 
a sequence-specific probe (not primer-tagged), as reported by Curtis et al.72, would be 
better suited for this type of assay.  
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Figure 21. Integrated on-chip assay with clinical cervical specimens. Table lists gold standard 
assay (Qiagen-extraction quantified by qPCR) results for HPV16 and RNaseP control DNA 
quantities for each of 10 patient samples labeled A-J. NEG = negative result. Chip LFD strip 
images for each sample A-J below. Test line intensity as percentage of control line intensity is 
plotted. 
	  	  
72 
It is also possible that cell debris and salts in the cervical samples left behind on 
the sample port are affecting our primer melting temperatures in ways we are unable to 
account for. While further primer and/or probe optimization may be required, herein we 
have demonstrated that a fully integrated, sample-to-answer, molecular diagnostic assay 
on a low-cost, disposable paperfluidic chip platform is possible.  
Furthermore, it is known that with HPV testing clinical false-positive results 
(positive screening tests without underlying precancerous lesions) are common73, largely 
due to transient levels of HPV infection in any given population that may never develop 
into cervical intraepithelial neoplasias or cancer. Consequently, American Cancer Society 
guidelines do not recommend screening by HPV testing alone for most clinical settings, 
but as cotesting with cytology every 5 years in women over 3074. In resource-limited 
settings, where cotesting is likely not an option, our paperfluidic diagnostic platform 
allows for primary HPV screening, where a positive result can be followed up by 
cytology, thereby allocating precious resources to those most at risk. A recent systematic 
review concluded that HPV testing alone is very promising for the primary screening of 
women aged 30 years and older, particularly when coupled with cytology testing for 
follow-up of HPV-positive results, which may reduce the number of false-positive 
findings that would result from HPV testing60,75. A study in Brazil indicated that HPV 
testing followed by cytology triage could be a very cost-effective strategy for lower-
middle income countries, results reflecting a synergistic effect between a highly sensitive 
initial screening test (HPV DNA) in sequence with a highly specific test (cytology)76. In 
extremely resource-limited countries, use of a simple, low-cost HPV DNA test like the 
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one presented here, followed by immediate ‘screen and treat’ strategies based on low-cost 
methods like VIA in those who test positive, is likely to minimize the number of patient 
visits and make best use of limited resources77.  
Based on these studies and recommendations, our suggested algorithm for use of 
our chip for cervical cancer screening protocols would be to use this low-cost, portable 
platform to easily screen all eligible women in a given population, and triage any positive 
results to further cytological screening, where pre-cancerous lesions (if evident) can be 
immediately treated. Given this strategy, our current assay errs on the side of safety, as a 
false positive result would merely result in an extraneous cytological exam. 
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
 
The body of work presented in this thesis culminated in the design and 
development of a sample-to-answer paperfluidic molecular diagnostic platform 
prototype. Preliminary work focused on the development of separate NAAT modules for 
the extraction, amplification, and detection of nucleic acids from clinical samples directly 
within a paper matrix. A paper-based assay was developed for the extraction and 
purification of Influenza A (H1N1) RNA directly from patient nasopharyngeal 
specimens, in situ isothermal RT-LAMP amplification, and immediate lateral flow 
detection of amplified products. The detection limit of the paper-based assay was 106 
cp/mL, suitable for the vast majority of reported patient flu viral loads at the onset of 
symptoms. The assay required no instrumentation other than a heat block, and the total 
sample-to-answer assay time was 45 minutes, making it a suitable starting point for the 
development of a rapid diagnostic.  
The next challenge was to integrate all three paper-based NAAT modules onto a 
single platform that would be low-cost, simple to use, portable, disposable, and 
independent of electricity or equipment. A paperfluidic chip was designed from low-cost 
paper and adhesive materials that allowed for directional control of fluid flow through 
pre-perforated fold and rip valves. The chip consists of a sample port made of 
polyethersulfone that serves as a nucleic acid extraction matrix as well as an 
amplification chamber, an absorbent pad that acts as a sink for all fluidic waste, and an 
immunochromatographic lateral flow strip for immediate visual detection of amplified 
products.  
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 We demonstrated full sample-to-answer functionality of our chip by 
implementing an HPV 16 DNA extraction, amplification, and detection assay directly 
from patient cervical samples. Our on-chip HPV 16 assay addresses many of the 
limitations of conventional cytology by providing highly sensitive molecular level 
information regarding the presence of high-risk HPV 16 in cervical samples without the 
need for laboratory infrastructure or highly trained pathologists.  
The chip also addresses the limitations of current molecular diagnostic techniques 
by allowing for rapid, point-of-care detection in less than an hour without the need for 
transportation to/from a laboratory. This device can be employed in low-resource settings 
and has the potential to reach a larger pool of patients who may otherwise not get 
diagnosed due to insufficient resources and personnel. Furthermore, this paperfluidic chip 
has the potential to serve as a molecular diagnostic platform for any disease, requiring 
only changing of primer sequences and the corresponding optimization of LAMP assay 
conditions. The versatility and simplicity of the platform described herein has the 
potential to be a powerful tool in early detection and lowering the burden of infectious 
disease in the developing world. 
While we achieved some success with our initial chip prototype, future work will 
be required to address some of the current limitations of the technology before 
implementation in the field can be realized. Currently, the chip requires an external 
source of heat for the isothermal amplification step. The work presented here was 
performed using a heat block but this can also be achieved through several methods that 
do not require electricity such as battery operated resistance heaters15 and even toe 
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warmers16. Nonetheless, incorporating an integrated heating system within the 
paperfluidic platform would greatly increase its portability and usability. Something like 
a solar powered strip heater that could be attached to the bottom of the chip and peeled 
open when ready to heat could be a possible future direction. 
An additional limitation to the current chip design is that it requires a significant 
amount of pipetting and manipulation by the user. A number of variables can be 
optimized to limit the number of steps, for example, increasing the surface area of the 
sample port, or optimizing buffers and assay conditions to reduce the volume needed. 
Furthermore, the current reagents used for the amplification reaction require cold storage, 
which may not be readily available in remote settings. Thus, future work should include 
the lyophilization of reagents directly into the sample port paper matrix that can be 
hydrated upon use. 
Other challenges encountered during this work revealed key weaknesses of our 
current isothermal amplification method: LAMP. It has been well documented in the 
literature that spurious amplification is a common problem with LAMP, due to the high 
likelihood of interactions and self-priming of two or more of the six primers involved. 
While in the laboratory we are able to distinguish spurious amplification using our 
restriction enzyme digest method, our current on-chip detection method is an end-point 
lateral flow strip (LFS) assay that will detect any amplified product that contains a FITC 
probe. Because the FITC probe is currently tagged to one of our primers, extension from 
this FITC-tagged primer will obviously occur. In the event that this primer (or any 
extended region from this primer) interacts nonspecifically with other primers or 
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amplicons, this will result in a false positive test. This problem will only become worse 
as future work in multiplexing the assay introduces double the amount of primers into our 
reaction. Thus, as a final component of this thesis, we began brainstorming potential 
solutions and ways to minimize the nonspecific detection of spurious LAMP 
amplification. 
We recently began testing our latest hypothesis that a sequence-specific probe 
would be better suited for our end-point detection assay than the primer-tagged probe 
method we currently use. To test our hypothesis, we aimed to design a target sequence-
specific probe that is 3’-blocked so that it cannot extend but can only hybridize with the 
correct product. While we felt confident that this should reduce LFS detection of spurious 
amplification, we were unsure whether enough of the probe would remain hybridized, 
even with the polymerase’s ongoing strand displacement activity, to produce a visible 
signal on the LFS. If too much of the probe gets displaced and a strong enough signal is 
not acquired, an additional high temperature polymerase-kill step may be required. 
As a preliminary test, we removed the 5’-FITC tag from the forward loop primer, 
and moved it to the 3’ end. This effectively removed the forward loop primer from the 
reaction, meaning amplification would occur with just the remaining 5 primers, and 
instead this 3’-FITC tagged oligonucleotide would serve as an HPV16-specific probe. 
This way, we ensure that the probe will be specific to the target and will be far less likely 
to interact with the primers. Thus, any spurious amplification should not be detected on 
the lateral flow strips and could increase the specificity of our assay detection method. 
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Figure 22. Schematic of probe test conditions. Left panel: Primer-tagged probe (control 
reaction). Here, the forward loop primer is tagged with a 5’-FITC, thus extension occurs from this 
primer and FITC is incorporated into amplicons. Right panel: Sequence-specific probe. Here, the 
forward loop primer is tagged with a 3’FITC, thus preventing extension and only allowing 
hybridization with the correct product. 
 
 We ran our control LAMP reaction (Figure 22, left panel), as well as our 
sequence-specific probe test (Figure 22, right panel) where we simply swapped out the 5’ 
FITC-tagged forward loop primer and replaced it with our new 3’ FITC-blocked forward 
loop sequence probe. For each reaction we tested 10^5 total copies of HPV 16 DNA, 
10^5 total copies of HPV 18 DNA (other DNA negative control), and a water condition 
(no template negative control), each in triplicate. We ran the reaction at 63°C for a full 
hour, instead of the normal 30 minutes, in an attempt to increase the probability of 
spurious amplification and really test our system. All other reaction conditions remained 
the same.  
 Results are shown in Figure 23. Per usual, we ran the amplified products on a 2% 
agarose gel analyzed by ethidium bromide (EtBr) staining (Figure 23a) and concluded 
that amplification successfully occurred for HPV16 conditions in both the control and 
sequence specific probe test reactions. At this lower resolution, there did not appear to 
have occurred any spurious amplification in any of the negative control conditions. 
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Additionally, prior to EtBr staining, we imaged the gel for FAM fluorescence and 
determined that the FITC probe had successfully hybridized to the amplified products 
(Figure 23b).  
	  
Figure 23. Sequence-specific probe test results. A) 2% agarose gel of amplified products 
stained with Ethidium Bromide. L = 100bp ladder, 16 = 10^5 copies of HPV 16 DNA, 18 = 10^5 
copies of HPV 18 DNA, NTC = no template control. B) 2% agarose gel of amplified products 
imaged under FAM fluorescence. C) 10% acrylamide gel of PvuII-digested LAMP products 
stained with SYBR green dye. L1 = pBR322 DNA-MspI Digest Ladder, L2 = EvaGreen 
Fluorescent DNA Ladder. D) 10% acrylamide gel of PvuII-digested LAMP products imaged 
under FAM fluorescence. E) Lateral flow strip test results. 
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Next, we digested the amplified products (only one of three triplicates for each 
condition) using the PvuII restriction enzyme and analyzed the digests on a 10% 
acrylamide gel (Figure 23c). Both the control and sequence specific probe reaction 
conditions showed the expected digest band pattern for HPV 16 only. The same gel was 
imaged for FAM fluorescence. This FAM assay (developed by Winnie Wong, a graduate 
student in the Klapperich Lab) serves as an intermediate readout between our regular gels 
that show all amplified products and our LFS detection assay that detects FITC-tagged 
products. With it, we are able to determine which digested product bands actually contain 
the FITC probe that will be detected on our LFS. As seen in Figure 23d, only one of the 
bands (53bp) contains the FITC probe, resulting in a much cleaner readout for detection 
of specific products during assay development. In Figure 23c, under the NTC condition 
for the probe test, it appears as though spurious amplification occurred in this reaction, 
but this was not detected on the FAM gel, suggesting that the sequence-specific FITC 
probe did not hybridize to these nonspecific products and that this spurious amplification 
would not result in a false positive on the LFS. Finally, we ran the undigested LAMP 
products on our LFS and as we hypothesized, only the correct HPV16 products were 
detected on the strips (Figure 23e). 
 These results confirm that our sequence-specific probe method works very 
similarly to our control method in terms of amplification and production of a sufficient 
detection signal on the strip. Thus, an additional high temperature polymerase-kill step is 
not required, which allows us to maintain a truly isothermal assay. While spurious 
amplification did not occur in our control condition, one of the NTC conditions in the 
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probe test reaction did show spurious amplification on a higher resolution acrylamide gel 
that was not detected by our sequence-specific probe. This demonstrates that our 
sequence-specific probe method is a simple way of improving our assay to reduce 
detection of spurious amplification. While further optimization work may be required, 
this new method could increase our LFS assay specificity and hopefully minimize the 
challenges of multiplexing LAMP moving forward. 
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APPENDIX: OTHER DOCTORAL WORK 
In August 2011, I began my doctoral thesis in the Tissue Microfabrication 
Laboratory of Dr. Christopher Chen at the University of Pennsylvania. Our lab moved to 
Boston University in September of 2013, where I decided to apply my microfabrication 
expertise to solving global health challenges and transitioned to Dr. Catherine 
Klapperich’s laboratory. The work presented in this Appendix is the culmination of my 
work in Dr. Chen’s lab during the first two years of my PhD, which has not been 
previously included in any other dissertation. This work was published125 and has been 
adapted in this appendix with permission from Rodriguez, N. M., Desai, R. A., 
Trappmann, B., Baker, B. M., Chen, C. S. (2014). Micropatterned multicolor dynamically 
adhesive substrates to control cell adhesion and multicellular organization. Langmuir, 30 
(5),1327–1335. Copyright 2014 American Chemical Society. 
 
MICROPATTERNED MULTICOLOR DYNAMICALLY ADHESIVE 
SUBSTRATES TO CONTROL CELL ADHESION AND MULTICELLULAR 
ORGANIZATION 
 
Introduction 
 The ability to control the spatial localization and geometry of cells via surface 
engineering has contributed greatly to our understanding of how cell adhesion regulates a 
wide variety of cellular functions. Microcontact printing of adhesive proteins, a surface 
patterning tool based on soft lithography techniques developed by Whitesides et al., 
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restricts cell adhesion to specific regions78-82 and has enabled numerous studies 
illuminating mechanisms by which cell adhesion and shape impact cell survival, 
apoptosis, proliferation, differentiation, and migration83-87. However, micropatterned 
surfaces generated via conventional microcontact printing are binary: one region 
permanently permits cell adhesion, and the remaining region permanently prevents cell 
adhesion. Thus, conventional microcontact printing is not well suited to pattern more than 
two regions and does not allow for the patterning of multiple cell types. 
 To overcome this limitation, subsequent patterning techniques allowed for the 
fabrication of multicolor substrates via sequential stamping with multiple proteins88, 
multimask photolithography89, photoresist barriers and aminosilane-linked 
biomolecules90-92, multilevel stamps 93, and stamp-off 94. These multicolor substrates 
comprised more than one type of adhesive region and have been used to spatially 
segregate different cell types or subcellular components by exploiting the preferential 
attachment of certain cell types or receptors to specific adhesive ligands. However, 
because these techniques depend on this preferential attachment, their applicability is 
restricted to a very narrow range of cell types that have unusual adhesion specificities.  
Most cell types adhere promiscuously to a wide range of shared adhesive ligands, 
preventing selective adhesion as a strategy for patterning multiple cell types. 
Additionally, these multicolor substrates do not allow for cells to be released from initial 
patterns and are thus not applicable to studies of cell migration or multicellular 
organization.  
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 More recently, dynamically adhesive substrates have overcome many of these 
limitations by allowing for the non-adhesive region to be controllably induced to become 
adhesive via light exposure, electroactive or thermally responsive polymers, or physical 
masks95-110. These dynamically adhesive substrates allow for robust co-culture patterning 
where a first cell type is seeded on initial patterns, and a second cell type is seeded 
immediately upon induced adhesiveness of the remaining non-adhesive regions. These 
dynamic substrates also allow for studies of cell migration where initially patterned, 
restricted cells are released from their patterns upon an induced change in the substrate, 
thus allowing for temporal control of the onset of cellular shape changes or unrestricted 
migration.  Although these dynamic substrates facilitate a much wider range of 
applications than conventional micropatterned substrates, they are still limited by the fact 
that they are comprised of only two regions: the initially patterned region and the 
surrounding dynamically adhesive region. Thus, although they allow for cell migration 
following the adhesive switch, the subsequent surface is now essentially unpatterned so it 
no longer controls the path and direction of cell movement. Comprising only two regions 
also limits the complexity of co-culture pattern geometries one can achieve since only the 
first cell type geometry can be controlled and the second cell type would simply fill in the 
surrounding surface area. In order to realize configurations in which both cell types are 
patterned independently of one another, or where the pattern of cell movement once cells 
are released from initial patterns is controlled, a third permanently non-adhesive region 
becomes necessary. 
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 Here, we present a simple strategy based on the avidin-biotin interaction to 
generate multicolor patterned substrates that allow for three spatially and functionally 
distinct regions: adhesive, dynamically adhesive, and non-adhesive. Incorporating this 
third, nonadhesive region enables control over the initial pattern geometry as well as the 
geometry of switched areas. In this paper, we describe two applications of this technique: 
migration and co-culture. In migration studies, our technique now allows for spatial 
control over the path and direction of migration in addition to temporal control of the 
onset of migration. In co-culture applications, our technique now allows for the 
patterning of both cell types independently, with control of the non-adhesive spacing, and 
the ability to generate a wide range of interface geometries between two cell populations 
for different kinds of heterotypic cell-cell interaction studies. This simple method will 
enable studies of complex cellular organization and coordinated multicellular migration 
that better recapitulate tissue microenvironments in vitro. 
 
Materials and Methods 
Cell culture and reagents  
Human umbilical vein endothelial cells and human mesenchymal stem cells (Lonza, 
Walkersville, MD) were cultured as prescribed by the manufacturer. Chinese hamster 
ovary cells harboring Notch “Receiver” and Delta “Sender” transgenes, [Receiver line: 
CHO-K1-TREx + UAS-H2B-Citrine + CMV-H2B-Cerulean + CMV-hNotchECD-Gal4 
clone F1; Sender line: CHO-K1-TREx + TO-hDll1-mCherry] both graciously provided 
by Dr. Michael Elowitz (California Institute of Technology), were cultured as previously 
	  	  
86 
described111. Human plasma fibronectin (BD Biosciences, Bedford, MA) was 
fluorescently labeled using Alexa Fluor® 555 NHS ester (Invitrogen, Carlsbad, CA). 
Biotinylated fibronectin was obtained from Cytoskeleton, Inc (Denver, Colorado) or 
made in-house using Biotin-X, SSE, 6-((Biotinoyl)Amino)Hexanoic Acid, 
Sulfosuccinimidyl Ester, Sodium Salt (Sulfo-NHS-LC-Biotin), (Invitrogen, Carlsbad, 
CA) and fluorescently labeled using Alexa Fluor® 647 NHS ester (Invitrogen, Carlsbad, 
CA). Neutravidin and Neutravidin-Oregon Green 488 conjugate were obtained from 
Invitrogen. poly(dimethyl siloxane) (PDMS; Sylgard 184, Dow Corning, Midland, MI) 
was used at 10:1 (w:w) base:curing agent, Young’s modulus: ~1 MPa. 
 
Substrate Fabrication 
Patterned PDMS stamps were cast from a photoresist-patterned silicon wafer, as 
previously described112. Flat PDMS stamps were cast from a flat silicon wafer. For 
microcontact printing, PDMS stamps were inked by exposure to fibronectin or 
Neutravidin (50 mg/ml in PBS) for 1 hour at room temperature, then thoroughly rinsed in 
sterile water and blown dry with a stream of compressed nitrogen. In parallel, the cell 
culture substrate (PDMS-coated glass coverslip), was activated in an ultraviolet ozone 
cleaner (Jelight Company, Irvine, CA) for 7 minutes. The fibronectin-inked stamp was 
then placed in conformal contact with the substrate for at least 1 second. Next, the 
Neutravidin-inked stamp was placed in conformal contact with the substrate for at least 1 
second. For geometries that required precise alignment of the two stamps, stamp-off was 
used as previously described94. F127 Pluronics was then adsorbed to the PDMS surfaces 
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from a 0.2% (w/v) solution in sterile water for 1 hour at room temperature to prevent 
protein adsorption to non-stamped portions of the PDMS, and then rinsed thoroughly (at 
least three times) with PBS to remove any residual Pluronics F127. 
 
 
Cell seeding 
Cells were trypsinized and resuspended in serum-free culture media at an appropriate 
density for the pattern of interest (for sparsely patterned substrates like the cell pairs or 
single-track lines of 10-15 mm, seeding densities were kept low at ~5000 cells/cm2 of 
total substrate area; for large multicellular patterns, seeding densities were higher at 
~100,000 cells/cm2). Once cells spread to the extent of the fibronectin regions (2-24 
hours, depending on the cell type), a 10 mg/mL solution of biotinylated fibronectin in 
serum-free media was added to the substrates and incubated for 10 minutes at room 
temperature. Substrates were then rinsed twice with PBS to remove any uncaptured 
biotinylated fibronectin. For migration studies, substrates were immediately taken to an 
environmental chamber with temperature and CO2 control for live microscopy (In Vivo 
Scientific, St. Louis, MO). For co-culture patterning, the second cell type was seeded 
immediately after addition and rinse of biotinylated fibronectin at an appropriate density 
for the pattern of interest in normal, serum-containing, growth media. Once cells spread 
to the extent of the Neutravidin regions, substrates were rinsed three times with PBS to 
remove any unattached cells and incubated in growth media at 37 °C, 5% CO2. 
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Immunofluorescence and microscopy  
Substrates patterned with fluorescently-labeled proteins were imaged on a Nikon TE200 
or Nikon TE2000U microscope. For migration studies, cells were imaged using 
brightfield microscopy. To visually identify distinct cell types in patterned co-cultures, 
cell-types were labeled with the spectrally-distinct fluorescent dyes, CellTracker™ Red 
CMTPX and Green CMFDA (Molecular Probes). For labeling, cells were incubated in 
5uM Cell Tracker dyes for 30 minutes in serum-free media. Cells were then rinsed and 
incubated in serum-containing media for at least 1 hour.  
 
Quantification of adhesions and spreading 
To measure focal adhesions and cell spreading, we used the method used by Pirone et 
al.113 Briefly, cells were permeabilized with 0.5% Triton X-100 in cytoskeletal buffer, 
fixed in 4% paraformaldehyde in PBS, and immunolabeled for vinculin. Images were 
acquired with a 60x NA 1.4 objective on a TE2000U microscope with a Hamamatsu Orca 
CCD. Images were filtered and binarized to detect edges and remove background noise, 
and then segmented with a threshold of 0.25 mm2 to detect focal adhesions. The cell 
outline was manually traced to measure cell spread area. 
 
Measurement of migration parameters 
Live cells were seeded on the appropriate substrate, allowed to spread and image via 
transmitted light, time-lapse microscopy every 15 minutes. Cells were manually tracked, 
and the relationship of mean square displacement (MSD) versus time was fit using a 
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model that describes a persistent random walk: MSD=2S2P[t-P(1-exp{-t/P}]. Speed (S) 
and persistence time (P) were obtained from the curve fits, and reported. 
 
 
Results 
Fabrication of dynamically adhesive substrates 
 We developed an approach to generate multicolor substrates that comprise three 
distinct regions. Fibronectin is an adhesion protein that should always be adhesive to 
cells, but we reasoned that an alternative protein, Neutravidin, could be used as a 
dynamically-adhesive coating, and Pluronics F127 should be permanently non-adhesive. 
We used soft lithography techniques, as previously described 112, to micropattern regions 
of fibronectin (labeled with AlexaFluor 555) and Neutravidin (labeled with AlexaFluor 
488) on a PDMS surface, and simply backfilled the non-modified PDMS with Pluronics 
F127. 
 We generated patterns in two ways that depended on the precision of 
micropatterning demanded by the experimental application: low precision (‘Forward 
Printing’; Figure A1a, panel i) or high precision (‘Stamp-off’; Figure A1a, panel ii). For 
forward printing, we serially stamp fibronectin (illustrated in Red in Figure A1a) and 
Neutravidin (illustrated in Green in Figure A1a), manually rotating the stamps as needed 
(for example, by 90 degrees to generate orthogonal alignment (Figure A1a, panel I, steps 
1-2)). For experimental applications that demanded positioning of features at 
substantially higher spatial resolutions than achievable via manual stamp alignment (sub-
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millimeter scale), we used stamp-off (Figure A1a, panel ii). As an illustrative example in 
Figure A1a, panel ii, we patterned an array of 15x15 micron fibronectin squares within 15 
micron-wide lines of Neutravidin. This was generated by first inking a stamp of 15um-
wide lines spaced 100um apart with fibronectin, then deinking everything but the squares 
using a UV-ozone activated PDMS template (Figure A1a, panel ii, step 1), re-inking the 
same stamp with Neutravidin to fill in the gaps (step 2) (Neutravidin transfers only onto 
bare PDMS and not onto the previously printed fibronectin) and finally transferring the 
pattern to a cell culture substrate (step 3). The last step in both forward printing and 
stamp-off is to coat the remaining unstamped regions with Pluronics F127 to render them 
resistant to protein adsorption and therefore cell adhesion. Failure to add Pluronics F127 
results in pattern fouling. 
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Figure A1. Generating 3-color dynamically adhesive substrates via two microcontact printing 
techniques. (a) (i) Forward printing. (1) Transfer the fibronectin (red) on a previously inked stamp 
to the cell culture substrate. (2) Then transfer the Neutravidin (green) on a previously inked stamp 
to the same cell culture substrate by manually aligning features as needed. (3) Finally, incubate 
the substrate in 0.2% Pluronics F127 (w/v) in water for 1 hour to render the remaining regions 
non-adhesive. Fluorescent light (FL) micrograph shows an example of corresponding features. 
Scale bar, 100 μm. (ii) Stamp-off. 1) Use a UV ozone-activated template to stamp off undesired 
regions of fibronectin (red) from a previously inked stamp. 2) Re-ink the stamp with Neutravidin 
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(green). (3) Finally, transfer the fibronectin-Neutravidin pattern on the stamp to the cell culture 
substrate. Fluorescent light (FL) micrograph shows an example of corresponding features. Scale 
bar, 100 μm. (b) Switch mechanism. Neutravidin patterned regions are non-adhesive to cells, but 
will capture biotinylated fibronectin in solution to then become adhesive. Fluorescent light (FL) 
micrograph shows an example of corresponding features from (a i,ii) where biotinylated 
fibronectin labeled with AlexaFluor-647 attaches specifically to the Neutravidin regions and not 
the fibronectin regions (red) or the non-adhesive regions (black). Scale bar, 100 μm. 
	  
 Neutravidin, a deglycosylated version of avidin, is non-adhesive to cells; 
however, the extremely high affinity between Neutravidin and biotin (Kd ~ 1 x 10-15M) 114 
allows for immediate capture of biotinylated ligands from solution. We reasoned that by 
adding biotinylated fibronectin to the media, we could switch the Neutravidin region 
from cell non-adhesive to adhesive. The biotinylated fibronectin, (labeled with 
AlexaFluor 647 for protein visualization) binds specifically to the Neutravidin region 
(Figure A1b, i and ii) but not to the originally printed fibronectin. In this way we generate 
multicolor patterned substrates with three regions: adhesive (microcontact printed 
fibronectin), initially non-adhesive region (microcontact printed Neutravidin) that can be 
induced to become adhesive by the addition of biotinylated fibronectin, and non-adhesive 
(Pluronics F127).  
 It is important to note that while Pluronics is established as a non-fouling agent 
that degrades in a cell-independent manner115, it does have a finite lifespan that is likely 
limited by desorption from the surface. The Pluronics is physisorbed onto the substrate 
and others have reported that the presence of serum proteins in the media will eventually 
displace the polymer from the surface116, leading to eventual fouling of the nonadhesive 
area. Similarly, the Neutravidin region can indeed degrade likely due to cell proteases 
and remodeling. However, in combination the Neutravidin-Pluronics surface coating is 
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stable at least up to 2 days, and Pluronics surfaces alone have been reported by our group 
to be stable for up to 5 days115. Thus, while it is likely that the surface is remodeled over 
longer periods of time, we anticipate that this strategy can be used for shorter term 
experiments.”   
 
Characterization of the substrates 
 Because the fibronectin is stamped onto the surface, whereas the ‘switched’, 
biotinylated fibronectin is captured from solution by Neutravidin, there was a possibility 
that cells would respond differently to printed versus captured fibronectin. To investigate 
this, we examined three cell responses to these different fibronectin coatings: spread area, 
adhesive area, and random motility parameters. We used endothelial cells as our model 
cell, and adsorbed fibronectin as a control, since most studies typically adsorb fibronectin 
onto a cell culture surface such as a glass coverslip. We first examined cell spread area on 
the surfaces by culturing cells in the presence of serum for 24 hours, fixing them with 4% 
paraformaldehyde, staining them for F-actin with phalloidin, acquiring images of the 
phalloidin stains (Figure A2a) and finally processing the images to extract cell spread 
area (see Materials and Methods).  Figure A2b shows that cell spreading was statistically 
identical across adsorbed, printed, and captured fibronectin.  
 Although cells spread to a similar extent, it was unclear whether their underlying 
adhesion to the various types of fibronectin was similar. To test this, we quantified the 
number of focal adhesions across the cell on the three surfaces. Cells cultured for 24 
hours were permeabilized with 0.5% triton-X, and immunolabeled against mature focal 
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adhesions with an antibody that recognizes the focal adhesion protein, vinculin. Results 
showed that cells adhered statistically identically to printed and captured fibronectin, 
although they adhered statistically significantly more to adsorbed fibronectin than printed 
fibronectin (Figure A2c,d).  
 One output of cell adhesion is cell migration, so we next compared cell migration 
on the different surfaces. To compare cell migration, cells were seeded sparsely on each 
surface and tracked for a duration of 2-4 hours, approximately 12 hours after seeding. 
Trajectories of 10 illustrative cells are shown in Figure A2e. We confirmed that cells in 
this setting fit the persistent random walk model used to describe cell migration, 
consistent with prior expectations117,118. This model relates the mean square displacement, 
MSD, to time, t, as a function of cell speed, S, and persistence, P, and is of the form: 
MSD=2S2P[t-P(1-exp{-t/P}]. Although cell speed was statistically identical on all three 
surfaces (Figure A2f), persistence time (the average time between significant changes in 
direction) was substantially higher on adsorbed fibronectin compared to printed or 
captured fibronectin. Although we do not know what underlies this difference in 
persistence time, we suspect that it is related to the higher adhesive area observed for 
cells on adsorbed versus printed or captured fibronectin. Taken together, we conclude 
that cells behave statistically identically on printed and captured fibronectin although 
some differences between these coatings compared to adsorbed fibronectin exist. 
Importantly, our technique here relies on printed and captured fibronectin only, and not 
adsorbed fibronectin. We therefore consider our micropatterned fibronectin and 
Neutravidin strategy effective for comparing the behavior of cells adhering to 
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micropatterned fibronectin versus biotinylated fibronectin captured by Neutravidin. 
 
Figure A2. Characterization of cellular behavior on dynamically adhesive substrates. (a) Cell 
spread area is shown and (b) computed from HUVECs seeded on the indicated matrix for 24h, 
fixing and immunolabeling for F-actin. (c) Number of focal adhesions are shown and (d) 
computed from HUVECs seeded on the indicated matrix for [24h], fixing and immunolabeling 
for vinculin. (e) HUVECs were followed via time-lapse phase microscopy on the indicated 
substrates for 2-4h. Migration tracks, and mean-squared-displacement versus time was 
determined and fit to the persistent random walk model to describe cell migration. (f) The 
parameters speed and persistence time were computed from the model. Box and whisker plots are 
5-95%. Scale bars, 25μm. 
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Patterning cell migration 
 Since cells behave similarly on printed and captured fibronectin, we patterned 
these to make dynamic substrates, first to ask whether we could control both the onset 
and direction of migration of cells. To test how quickly cells would respond to the 
Neutravidin regions’ induced adhesivity, we confined cells to small, 35x35µm square 
islands (Figure A3a), and then switched the adhesivity of the surrounding Neutravidin 
region by adding biotinylated fibronectin to allow cells to begin migration. Ten cells in 
the field of view were tracked before and after the addition of biotinylated fibronectin. 
Plotting their trajectories before and after addition of biotinylated fibronectin (Figure 
A3b) demonstrates that cells are initially confined to the square islands, but become 
migratory after the addition of biotinylated fibronectin. Plotting displacement versus time 
(Figure A3c), shows that cells transition from stationary to migratory almost immediately 
after addition of biotinylated fibronectin. This highlights the rapidity with which we can 
induce the onset of single cell migration. 
 Previous methods have also shown the ability to temporally control the onset of 
migration through removal of physical constraints or electroactive, thermal, or 
photoactivated switching95-100,102-110. Our approach can not only temporally control the 
onset of migration as above, but with three-color patterns we can also constrain the path 
and direction of cell migration by patterning non-adhesive regions. To demonstrate 
control over both the onset and path of cell migration, single cells were seeded on an 
array of 15x15 µm fibronectin squares embedded within 15 µm wide Neutravidin lines 
(Figure A3d, panels i,ii). Upon addition of biotinylated fibronectin to the culture media, 
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cells begin to migrate along the patterned Neutravidin lines but not the intervening space 
between the lines (panel iii). Cells were significantly more elongated after the addition of 
biotinylated fibronectin (panel iv), demonstrating that cells spread along the induced 
adhesive area. We can thus restrict cell migratory direction to pre-defined tracks, 
permitting ease of observation and analysis of cell migration119,120. Additionally, the 
versatility of this technique in terms of pattern geometry allows for increasing pattern 
complexity allowing for the generation of systems relevant to in vivo coordinated 
multicellular migration by changing pattern shape. 
 
Figure A3. Patterning cellular migration. (a) Phase contrast micrographs of HUVECs initially 
patterned on 35μm x 35μm printed fibronectin squares for 12h, and after the addition of 
biotinylated fibronectin to the culture to permit cell migration. Scale bars, 100μm. (b) Migration 
tracks were recorded from phase contrast images taken every 3 minutes, for 24 minutes before 
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addition of biotinyated fibronectin (blue lines), and 48 minutes after addition of biotinylated 
fibronectin (red lines). Scale bar, 10μm. (c) The distance from the initial point over time was 
computed. Individual cell curves are shown in gray, and the mean, and mean±sem of cells 
shown in the plot are shown in solid and dashed red curves, respectively. (d) Schematic showing 
technique to pattern cellular migration. In a separate experiment from (a-c), cells were seeded on 
a 3-color dynamically adhesive substrate. Scale bars, 100μm. (i) Cells attached only onto 
fibronectin regions (red) (ii). Biotinylated fibronectin was then added to the media and cells were 
free to migrate onto Neutravidin regions only (iii) thus restricted to pre-defined tracks. Ellipses 
were fitted to cells before and after adding biotinylated fibronectin, and the major/minor axis 
length was computed (iv). The box and whisker plot shows the 5-95% range, and the dotted line 
represent the major/minor axis ratio expected of a perfect circle (Major Axis/Minor Axis = 1). 
 
Patterning cellular co-cultures 
 How signals propagate throughout multicellular structures is another important 
area of investigation in developmental biology to which multicolor patterns could greatly 
contribute. Although prior approaches to dynamically adhesive substrates have permitted 
co-culture patterning through the use of stencils, electroactive switching, and selective 
adhesion90-92,95-100,102,103, these were limited to two-color patterns and thus were unable to 
realize configurations of complex interfacial geometries where both cell-cell contact and 
spacing between the different cell types could be controlled. In contrast, our three-color 
dynamic substrates allow us to micropattern much more complex configurations of 
cellular co-cultures for diverse studies of heterotypic cell-cell interactions. To accomplish 
control over the patterning of two cell types on a three-color substrate, one population of 
cells was seeded and grown to confluence to fill the initial fibronectin pattern.  Once the 
cells spread to the full extent of the fibronectin region, biotinylated fibronectin was added 
to the culture media and a second cell population was seeded, which quickly attached to 
the “switched” Neutravidin region (Figure A4a). We engineered a number of different 
geometrical interfaces between different cell types in large multicellular patterns as well 
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as at single-cell resolution (Figure A4, panels b-e) and demonstrate that we are able to 
control the size, shape, and curvature of the interface in patterned co-cultures. The 
simplicity of this technique also allows for much versatility in terms of being applicable 
to all or most cell types. Here, we have demonstrated patterning with human 
mesenchymal stem cells (Figure A4b), human umbilical vein endothelial cells (Figures 
A4d,e), and Chinese hamster ovary cells (Figures A4a,c). While higher resolution 
patterns consisting of fewer cells (Figures A4b, c) can be achieved very cleanly, larger 
multicellular patterns (Figures A4d,e) show a minor amount of cross-over of the cell 
types due to any existing gaps in the first cell monolayer in which the second cell type is 
free to land upon subsequent seeding. While we can minimize this by seeding the first 
cell type at higher densities and waiting for complete confluence, there will always be 
some inherent noise in the patterning because these are living, biological systems that 
have processes we cannot control. Nonetheless, we are able to demonstrate patterning of 
large (millimeter-scale) multicellular structures with relatively clean heterotypic 
interfaces. 
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Figure A4. Patterning cellular co-cultures. (a) Schematic showing technique to pattern cellular 
co-cultures. One population of cells is initially seeded on a 3-color dynamically adhesive 
substrate and can only attach to patterned regions of fibronectin (red) and not onto Neutravidin 
regions (green) or nonadhesive regions (black). After first cell population fills the fibronectin 
region completely (cells are cultured for 24 hours in serum-free media), biotinylated fibronectin 
(cyan) is then added to the media. The second population of cells is immediately seeded, and can 
attach to the “switched” Neutravidin regions, but not the non-adhesive regions (black). (b) Top 
panel: A fibronectin triangle (red) patterned adjacent to a Neutravidin triangle (green). Bottom 
panel: A single cell (MSC labeled with CellTracker Red) was initially seeded and was only able 
to attach to the fibronectin region. Biotinylated fibronectin was added to the media and a second 
cell type (MSC labeled with CellTracker Green) was then able to attach to the “switched” 
Neutravidin region thereby generating a patterned co-culture of heterotypic cell pairs. (c) Top 
panel: Single cell-wide lines of Neutravidin (green) are patterned perpendicular to a single cell-
wide line of fibronectin (red). Bottom panel: Two separate cell types (Notch-Delta harboring 
CHO cells) were patterned in co-culture for signal propagation studies. (d) Top panel: Annulus 
fibronectin pattern (red) and surrounding Neutravidin pattern (green). Bottom panel: HUVECs 
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labeled with CellTracker Red were seeded on the fibronectin pattern; once the fibronectin annulus 
was completely seeded, biotinylated fibronectin was added and HUVECs labeled with 
CellTracker Green were seeded on the “switched”  Neutravidin regions. (e) Top panel: 
Sinusoidal wave patterns of fibronectin (red) and Neutravidin (green). Bottom panel: HUVECs 
seeded as in (d). Scale bars, 100 μm. 
 To illustrate the utility of such patterns of co-culture, we examined an important 
question of interfacial juxtacrine signaling. Heterotypic cell-cell interactions occur at 
interfaces between two cell types and are commonly used in biological systems to 
orchestrate developmental processes such as proliferation, migration, differentiation, and 
tissue pattern formation. A receptor-ligand pair that mediates cell-cell interactions in a 
broad range of developmental patterning processes is the signaling pathway between the 
Notch receptor on one cell and the Delta ligand on an adjacent cell121-123. Recent 
quantitative studies of the Notch-Delta interaction using genetically engineered cell lines 
to visualize the interaction in real time has shed considerable light on novel mechanisms 
of the interaction111. To test whether the methods we have developed here could be used 
to further probe Notch-Delta interactions, we generated patterned co-cultures of Notch 
receptor and Delta ligand expressing cells and confirmed activation of Notch at the 
interface between the two cell types (Figure A5). We micropatterned a co-culture of 
tetracycline-inducible Delta expressing sender cells on the vertical fibronectin line, 
followed by Notch receptor cells with yellow fluorescent protein (YFP) reporters of 
Notch activity111 on the horizontal Neutravidin lines. Before addition of tetracycline 
(panel A5a; t=0), no sender cells express Delta and therefore no receiver cells harbor 
baseline Notch activity, as evidenced by baseline levels of YFP fluorescence. However, 
Delta was induced in sender cells upon addition of tetracycline, which then activated 
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Notch signaling in neighboring receiver cells, visualized by YFP expression localized to 
cells at the intersection of the vertical and horizontal lines within 24 hours after addition 
of tetracycline (Figure A5b).  Average YFP pixel intensity profiles clearly indicate a peak 
of Notch activation at the interface between sender and receiver cells (Figure A5c). We 
conclude that our three-color dynamic substrates offer an effective way to probe 
heterotypic interfacial juxtacrine signaling. 
 
Figure A5. Patterning interfacial juxtacrine signaling. Tetracycline-inducible Delta expressing 
sender cells were patterned on a vertical 10um wide fibronectin line, followed by Notch receptor 
cells with yellow fluorescent protein (YFP) reporters of Notch activity24 on the horizontal 10um 
wide Neutravidin lines. (a) Before addition of tetracycline, no cells express Delta and therefore no 
cells harbor Notch activity, as evidenced by baseline YFP fluorescence. (b) Delta is induced in 
sender cells upon addition of tetracycline, which then activates Notch signaling in neighboring 
receiver cells, visualized as YFP expression localized to the intersection of the vertical and 
horizontal lines approximately 24 hours after addition of tetracycline. (c) Average YFP pixel 
intensity profiles (taken from the entire images in a) and b) demonstrate peak Notch activation at 
the interface between sender and receiver cells. Scale bars, 100 μm. 
 
Discussion 
 We developed a technique that combines microcontact printing with a simple 
dynamic attachment chemistry to achieve multicolor patterns with three distinct 
functional regions: adhesive (microcontact printed fibronectin), non-adhesive (Pluronics 
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F127), and an initially non-adhesive region (microcontact printed Neutravidin) that can 
be induced to become adhesive by the capture of biotinylated fibronectin. We confirmed 
that cells spread, form adhesions, and exhibit motility to similar extents on captured 
biotinylated fibronectin as compared to printed fibronectin, thus making this an effective 
and powerful tool to examine cellular behavior. We then demonstrate the utility and 
versatility of this tool in studies of migration, cellular co-cultures and interfacial 
juxtacrine signaling.   
 Our technique offers several advantages over other current methods to generate 
dynamically adhesive substrates. Other methods include removal of physical 
constraints95,98,99, electroactive switching96,103,104, thermal- and photo-activatable 
polymers101,105-110, and layer-by-layer deposition124, but all of these have comprised only 2 
regions (adhesive and dynamically adhesive). These substrates enable control over the 
initial pattern geometry, but the lack of a non-adhesive region prevents control over the 
dynamically adhesive region. Our multicolor substrates comprise three spatially and 
functionally distinct regions that allow for independent control over the initial adhesive 
geometry, as well as the dynamically adhesive region. In migration studies, adequately 
patterning the non-adhesive region allows for spatial control over the path and direction 
of migration in addition to temporal control of the onset of migration. For co-culture 
applications, this three-color aspect now allows for the patterning of both cell types 
independently, with control of the non-adhesive spacing, and the ability to generate 
different interface geometries between two cell populations for diverse heterotypic cell-
cell interaction studies. It is important to determine that the second cell type to be seeded 
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will not undergo significant attachment to the first cell type as could be the case with 
some cell types. We present multiple cell types here (MSC, HUVEC, CHO) chosen for 
their biological significance in cell-cell interaction studies and did not see any significant 
attachment of one cell type onto another. 
 Other methods to pattern three distinct regions, such as Hui et al.’s patterned 
substrates of collagen, bare glass, and polyethylene glycol allowed for co-cultures of 
hepatocytes and fibroblasts in liver function studies, however, this depended on the rare 
selective adhesion of hepatocytes to collagen but not bare glass under serum-free 
conditions89. Our technique overcomes this restriction of selective adhesion by combining 
this three-color approach with the dynamic capture of biotinylated fibronectin, making it 
applicable to most or all cell types. One study did demonstrate dynamically adhesive 
substrates in three-color102, but this involved electrochemical switching to induce 
adhesivity of the dynamic region. Electroactive switching requires the use of a voltage 
pulse to the substrate, potentially affecting cell behavior, and is experimentally more 
complex as it requires electrochemical instrumentation.  This and many other dynamic 
substrate techniques, including physical membranes or stencils, are technically more 
challenging to implement than our method presented here, and may even cause physical 
damage to cells on the pattern edge. In contrast, our method allows for the induced 
adhesivity of a patterned region via the simple addition of a soluble factor, biotinylated 
fibronectin, to the culture media, that exploits the very common avidin-biotin bond to 
allow for cell adhesion and does not otherwise affect cellular adhesion, spreading, or 
migration. With proper characterization as presented here in Figure 2, this technique can 
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in principle be generalized to any solution capture method, via printed antibodies to 
capture a target protein, or Neutravidin and other biotinylated proteins. We believe that 
the simplicity of the method makes it extremely versatile and a promising approach in 
recapitulating the complexity of in vivo coordinated migration and cell-cell interactions. 
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